













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 




Identification of Targets of                                      
Human Cytomegalovirus microRNAs by                   
Cross Linking and Analysis of cDNA (CRAC). 
 











College of Medicine and Veterinary Medicine 
Royal (Dick) School of Veterinary Studies 
The Roslin Institute 
University of Edinburgh 
 
Thesis submitted for the fulfilment of the requirements                                                                  
of a Master of Science by Research Degree 2012 
 
Supervisor: Dr Finn Grey 
  
 
Funded by the BBSRC and the Wellcome Trust 
     
 
i 
Stephen M Chiweshe  CRAC 
Declaration 
I declare that this thesis has been composed by myself, Stephen Masaka Chiweshe, and the 
work presented is my own original work unless where otherwise indicated and all work of 
other authors is duly acknowledged. This work does not form part of a thesis presented 
successfully for a degree in this or another University. 
 
 


















Stephen M Chiweshe  CRAC 
Acknowledgements 
I would like to express my sincere and greatest appreciation and gratitude to Dr Finn Grey 
for giving me the opportunity to work on this project and the extensive immeasurable 
support he gave me through the year. I would like to thank Dr Natalie Reynolds for the help, 
support and tips in the laboratory as well as proof reading my thesis. Mr Jonathan Andrew 
Pavelin for, I don’t know - being a member of the group perhaps, mainly preliminary 
knowledge and skills with the CRAC that was transferred productively as well as support 
here and there and “a wee bit” of entertainment in the lab. Many thanks to the Dr Amy 
Buck and group for very useful CRAC tips and emergency reagents supply when we most 
needed them. A huge thank you to ARK genomics for our cDNA sequencing (at a cost, thanks 
to Dr Grey and funding for payment) and the on-going results analysis.  I would to say thank 
you to all the other groups in the lab for the help they gave during the year, discussions and 
cake breaks now and again. Last but not least, a massive shout out to friends and family, 
with a special mention to Mrs Sue Dixon and Mrs Karen Binch, for the encouragement and 
mainly for leaving me be when I wanted to be left be, also for the support in different forms 













Stephen M Chiweshe  CRAC 
 
List of Abbreviations 
2ME  2-Mercaptoethanol 
Ago-2  Argonaute 2 
α  Alpha 
β  Beta 
CCMV  Chimpanzee cytomegalovirus 
cDNA  Complementary deoxyribonucleic acid 
cm  centimetre  
CRAC  Crosslinking analysis of cDNA 
CTL  Cytotoxic T lymphocyte    
DC  Dendritic cell 
DNA  Deoxyribonucleic acid 
dsDNA  Double Stranded DNA 
DMEM  Dulbecco’s Modified Eagle Medium 
E  Early 
EBV  Epstein-Barr virus 
FACS  Fluorescence-activated cell sorting  
FBS  Foetal Bovine Serum 
GFP  Green Fluorescence Protein 
gN*  Glycoprotein (N*= B/L/M/N/O) 
HCMV  Human cytomegalovirus 
HSC  Haematopoietic stem cell 
HEK  Human embryonic kidney 
HIV  Human immunodeficiency virus 
HITS-CLIP High-Throughput Sequencing of RNAs isolated by Crosslinking 
Immunoprecipitation  
HV  Herpes virus  
HSV1  Herpes Simplex Virus type 1 
hpi  hours post infection 
hrs  Hours 
IgG  Immunoglobulin G 
IL  Interleukin  
IE  Immediate early 
IP  Immunoprecipitation 
IRS  Internal repeat short 
kb  kilobases 
kDa  kilo Daltons 
 
iv 
Stephen M Chiweshe  CRAC 
KSHV  Kaposi Sarcoma Herpes Virus 
L  Late 
MHC  Major Histocompatibility Complex 
MIE  Immediate early 
miRNA  Micro ribonucleic acid 
mJ  millijoule  
N/A  Not Applicable 
oriLyt  Origin of Lytic Replication 
µg  microgram 
µl  microlitre 
ml  millilitres  
mRNA  Messenger ribonucleic acid 
MT  Microtubule 
nm  nanometres  
NKG2D  Natural Killer cell protein Group 2D 
ORF  Open reading frame 
PBM  Peripheral blood mononuclear 
Pri-miRNA Primary miRNA 
Pre-miRNA Precursor miRNA 
PAR-CLIP  Photoactivatable-Ribonuclease enhanced Crosslinking and 
Immunoprecipitation 
Pol II Polymerase II 
PRG1  Plasticity related gene 1  
RISC RNA induced silencing complex 
THBS1 Thrombospondin 1 
PCR Polymerase Chain Reaction 
qRT PCR Real Time quantitative Reverse Transcription PCR 
TRL Terminal repeat long 
TRS Terminal repeat short 
UTR  Untranslated region 
UL  Unique long 








Stephen M Chiweshe  CRAC 
 
List of Figures 
Figure 1.1 Structure of the Herpes Viruses…………………………………………………..…………….….1 
Figure 1.2  HCMV Genomic Arrangement……………………………………………………..……….………4 
Figure 1.3 miRNA Biogenesis…………………………………………….…………………………………………13 
Figure 1.4 HMV miRNA Gene Map……………………………………………………………………………….16 
Figure 1.5 A schematic representation of the RISC-IP procedure…………………………………23 
Figure 1.6 Schematic representation of the HITS-CLIP procedure..…………………..…….…..24 
Figure 1.7 Overview of the PAR-CLIP procedure……………………………………………….…...……26 
Figure 3.1  Double Tagged Ago-2 Protein………………………………………………………………………33 
Figure 3.2 UV Crosslinking……………………………………………………………………………………………34 
Figure 3.3  Modified Steps of CRAC……………………………………………………………………………….35 
Figure 3.4 Representations of the Intra-molecular Ligation and Radioactive Labelling...36 
Figure 3.5 A cDNA Fragment for Deep Sequencing…………………………………..……………….…37 
Figure 3.6 Outline of the Illumina Genome Analyser Workflow…………………………….….….38 
Figure 3.7 Transfection Optimisation Results……………………………………………………………….39 
Figure 3.8 Induction Check Results……………………………………………..………………………….……40 
Figure 3.9 Dynabeads Conjugation Check & Effect of Lysate Concentration on IP…….….42 
Figure 3.10 Plasmid Map……………………………………………………………………………..………….…....43 
Figure 3.11 CRAC Attempt 2 Gel results………………..……………………………………………….………44 
Figure 3.12 Small Sequencing Result Demonstration……………………………………………….….…46 
Figure 3.13 CRAC Attempt 3 Gel results…………………………………………………………………….…..47 
Figure 3.14 CRAC Attempt 4 Gel results…………………………………………..…………………….………49 
Figure 3.15 CRAC Attempt 5 Gel results……………………………………………..………………….………51 
Figure 3.16 CRAC Attempt 6 Gel results…………………………………………..……………………….……52 






Stephen M Chiweshe  CRAC 
 
List of Tables  
Table 1.1 Human infecting herpes viruses ……………………………………………………………………2 
Table 1.2 HCMV encoded miRNAs………………………………………………………………………………18 
Table 2.1 Fugene:DNA Ratios……………………………………………………………………………………29 
Table 3.1 CRAC Attempt 2 Small Sequencing Results……………………………………………..…46 
Table 3.2 CRAC Attempt 3 Small Sequencing Results……………………………………………..…48 
Table 3.3 CRAC Attempt 4 Small Sequencing Results……………………………………………..…50 
Table 3.4 CRAC Attempt 5 Small Sequencing Results………………………………………………..52 
Table 3.5 CRAC Attempt 6 Small Sequencing Results………………………………………………..54 



















Stephen M Chiweshe  CRAC 
 
Abstract 
The discovery of a class of small ribonucleic acid (RNA) molecules known as microRNAs 
(miRNAs) has led to extensive interest in their biological relevance and role. The first miRNA 
was discovered in Caenorhabditis elegans in 1993. Since then studies have shown that 
miRNAs represent a fundamental mechanism of gene expression regulation, regulating 
thousands of genes at the post-transcriptional level. Given that viruses are highly adept at 
exploiting cellular processes, it is perhaps unsurprising they have evolved miRNAs of their 
own. The majority of known viral miRNAs are expressed by herpes viruses underscoring 
their importance to this virus family. Identifying the targets of herpes virus miRNAs would 
aid in elucidating the role played during infection. In this study, we aim to identify and 
understand the targets of the human cytomegalovirus (HCMV) encoded miRNAs using a 
cutting edge biochemical technique, Cross-Linking and Analysis of cDNA (CRAC).  
HCMV is a member of the beta (β) herpes virus subfamily and is globally distributed causing 
clinically asymptotic infections in immune competent individuals. However, persistent and 
recurrent infections in AIDS and organ transplant patients, who have a compromised 
immune function causes a high degree of mortality and morbidity. Intra-uterine infected 
infants are also at high risk with infection causing congenital abnormalities and mental 
retardation. Scientists worldwide are trying to understand one special characteristic of 
HCMV and herpes viruses in general, which is latency i.e. the presence of an intact viral 
genome in the cell with a majority of the genes in a dormant or silent state. Viral encoded 
miRNAs regulate both the viral genome as well as the host’s and this has been postulated as 
a latency inducing mechanism.  
To date, there are 22 known HCMV encoded miRNAs. On-going research in our group using 
techniques such as bioinformatics, RISC immunoprecipitation (RISC-IP) and microarray 
analysis has identified both viral and cellular targets of HCMV miRNAs. Targets include a 
crucial viral transactivator thought to play an important role in latency as well as cellular 
targets involved in a variety of functions including cell cycle control, intrinsic defence and 
innate cellular defence. However, the majority of HCMV miRNAs have no known function. 
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New approaches and technologies are required to elucidate the functions of these miRNAs. 
The initial goal of this project is to establish and optimise the CRAC technique. This will be 
performed in HEK293 cells transfected with a plasmid expressing a cluster of HCMV miRNAs 
termed miR-US25. The long-term goal of the project will be to use CRAC technology to 
identify miRNA targets in infected cells. 
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CHAPTER 1- Introduction 
1.1 Herpes Viruses 
The herpes viruses are a family of viruses that widely infects animals and humans. They are 
also referred to as Herpesviradae, a Greek derived word with a meaning inclining towards 
“latent” which is a characteristic of members of this family, i.e. latent infections. Members 
of this viral family have a general structure, illustrated in figure 1.1, made up of the core, 
capsid, tegument and envelope as the main components and these are key structures that 
are a prerequisite for a virus to be classified as a herpes virus. 
 
Fig 1.1: Structure of Herpes virus (Grundhoff and Sullivan, 2011). 
The core contains the viral DNA in a ring-shaped form known as the torus. The capsid is 
made up of 162 subunits known as capsomeres and has a diameter of approximately 
100nm. The tegument is the component between the capsid and the envelope, and exists in 
different thicknesses depending on the specific virus as well as the location of the virus 
within an infected cell. The tegument has the important role of transporting pre-synthesised 
proteins into the newly infected cells which have an immediate effect on host management, 
establishing a virus-favourable environment through activities such as shutting down the 
host protein synthesis, inhibiting infection-triggered cell defences, and stimulating viral gene 
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expression (Fields et al., 2007). The envelope forms the outer structure of the virus and is 
composed of lipids, glycoproteins and altered forms of the host membrane.  
Herpes viruses have a large double stranded DNA genome which varies from 124 to 239 kb 
in length and is linear but is known to circularise immediately upon release from the capsid 
into the infected cells’ nuclei. There are eight known human-infecting herpes viruses and 
they are classified into three subfamilies, Alphaherpesviranae (α), Betaherpesviranae (β) and 
Gammaherpesviranae (γ) (table 1.1). 
Table 1.1: Herpesviruses infecting Humans. 
Virus Name Abbreviation Vernacular Name Subfamily Genome size 
Human HV 1 HHV-1 Herpes simplex virus 1 α 152 
Human HV 2 HHV-2 Herpes simplex virus 2 α 155 
Human HV 3 HHV-3 Varicella-zoster virus  α 125 
Human HV 4 HHV-4 Epstein-Barr virus γ 172 
Human HV 5 HHV-5 Cytomegalovirus β 230 
 
Human HV 6 
HHV-6A HHV-6 variant A β 159 
HHV-6B HHV-6 variant B β 162 
Human HV 7 HHV-7  β 145 
Human HV 8 HHV-8 Kaposi’s sarcoma-
associated Herpesvirus 
γ 170 
HV: Herpes virus. Table adapted from Fields Virology (Fields et al., 2007). 
In addition to the structural features, the human herpes viruses have other common 
characteristics, including the conservation of what is known as the core genes across the α, 
β and γ subfamilies. These are 40 genes that encode for mainly structural, nucleotide 
metabolism or DNA replication proteins (Fields et al., 2007). Herpes viruses have evolved 
means and ways to enable their replication and survival in the highly non-favourable 
 
3 
Stephen M Chiweshe (s1161257) CRAC 
environment the host presents. One such mechanism is by blocking the induction of 
apoptosis or the interferon pathway (Fields et al., 2007, Miller et al., 2000). Herpes viruses 
are also known to employ a process known as molecular mimicry whereby some viral 
encoded proteins function as immunomodulators. The virus can also block the presentation 
of antigenic peptides on the surface of antigen presenting cells. These processes in turn 
result in a delay of the infected cells’ elimination, long enough to allow the replication and 
infection of new cells by the virus as well as the viral evasion of the immune system and 
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1.2 Biology of Human Cytomegalovirus 
 Human cytomegalovirus (HCMV) is a member of the β herpes virus subfamily and 
specifically infects humans. HCMV infection in immunocompetent individuals is 
asymptomatic but is a cause of significant morbidity and mortality in immunocompromised 
people such as, organ transplant recipients, intrauterine infected infants as well as AIDS 
patients where it causes opportunistic infections. 
1.2.1 Virion Structure 
HCMV, like other herpes viruses, have the general structure illustrated in figure 1.1. The 
virion has a diameter of approximately 200 to 300nm, one of the largest and structurally 
more complex in the Herpesviridae family. The HCMV genome is encompassed by the capsid 
and together the two components make an icosahedral nucleocapsid with a diameter of 
approximately 130nm. The tegument surrounds the nucleocapsid and comprises viral 
proteins, termed tegument proteins, as well as a selection of viral and cellular RNA (Fields et 
al., 2007). A selection of tegument proteins and the roles they play in HCMV infection are 
discussed in the lytic replication section below. On the outer layer of the virion is the 
irregular envelope, a lipid bilayer, which is partly made from altered host cellular 
membranes and has a vast number of glycoproteins that play a critical role in viral host cell 
entry. 
1.2.2 Genome Structure 
HCMV has the largest genome among the herpes viruses, which is in a linear double 
stranded form, of approximately 230 kb. The genome is made up of unique long (UL) and 
unique short (US) regions that are flanked by repeat regions as illustrated below. 
 
 
Fig 1.2: HCMV genomic arrangement. TRL: Terminal Repeat Long, IRL: Internal Repeat Long, 
IRS: Internal repeat Short, TRS: Terminal Repeat Short, UL: Unique Long and US: Unique 
Short (redrawn from (Fields et al., 2007)). 
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Recombination during replication leading to the inversion of these genome components 
generates four different genome isomers in equal amounts, which are all infectious. Work 
by Chee et al (1990) predicted that the HCMV genome encodes for 189 protein coding 
genes. This figure has since been reduced to a range of 164 to 167 after work comparing the 
closely related chimpanzee CMV (CCMV) sequence to the laboratory strains AD169 and 
Toledo genome sequences found that some of the open reading frames (ORFs) were not 
protein-coding genes (Davison et al., 2003). The exact number of ORFs is still difficult to 
determine as laboratory strains are obtained after a number of passages and they tend to 
undergo some genetic loss, mutations and rearrangements as they are passaged.  
1.2.3 Lytic Replication  
The lytic life cycle of HCMV follows a sequence of controlled events that commence 
immediately after binding of the virus to host cell receptors. By a mechanism that involves 
glycoproteins, particularly glycoprotein B (gB), one of the core proteins conserved in all 
herpes viruses, HCMV attaches to receptors on the cell surface and initiates its entry. 
Heparin sulphate, which is expressed on the host cell surface, is thought to act as a receptor 
for gB molecules. HCMV is understood to also use other envelope proteins such as 
glycoprotein H, L, M and O (gH, gL, gM and gO) for host cell binding. The two most reported 
mechanisms of entry are fusion between the viral envelope and the plasma membrane for 
entry into fibroblast cells, and receptor mediated, pH dependent endocytosis for entry into 
epithelial and endothelial cells (Bodaghi et al., 1999, Ryckman et al., 2008, Fields et al., 
2007). For entry into fibroblast cells, the glycoproteins gH, gL and gO have been 
demonstrated to interact and form a complex, gH/gL/gO, that interacts with host cells 
surface’s integrins leading to the direct fusion at the plasma membrane of the virion and a 
target host cell. The three proteins, UL128, UL130 and UL131, encoded by the UL128-131 
region form pentameric complexes with gH/gL and mediate HCMV entry into epithelial and 
endothelial cells also via integrin binding (Ryckman et al., 2008, Park et al., 2006). Upon 
entry of the virus into the host cell, the nucleocapsid is released into the cytoplasm and 
translocated to the nucleus by a cytoskeletal dependent mechanism and interacts with a 
nuclear pore allowing the release of the genome into the nucleus.  
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Lytic replication of the HCMV genome starts with the expression of the viral immediate early 
(IE) genes as soon as the viral DNA reaches the host cell’s nucleus. This is followed by the 
expression of the early (E) genes, viral DNA replication and then late (L) gene expression. 
Encapsidation of the viral genome followed by release of an infectious virus concludes the 
lytic life cycle (Johnson et al., 2001). Efficient and successful delivery of the viral genome to 
the host’s nucleus is facilitated by important tegument proteins which also initiate viral gene 
expression (Kalejta, 2008). Upon entry of the HCMV nucleocapsid into the cell, the first 
barrier to reaching the cell’s nucleus is the high cytoplasm density as well as the size of the 
nucleocapsid. To circumvent this, the virus uses the intracellular transport machinery, 
travelling along microtubules (MTs) (Ogawa-Goto et al., 2003) with the aid of some tightly 
associated tegument proteins such as the UL32 encoded pp150, as well as the UL47/UL48 
protein complex (Bechtel and Shenk, 2002, Kalejta, 2008). The UL47/UL48 protein complex 
also plays a role in the injection of the viral DNA into the cell’s nucleus via the nuclear pore 
complex. Work performed on herpes simplex virus type 1 (HSV1) found similar complexes 
formed by the pUL37 and pUL36, also called VP1/2 respectively that migrate along the host 
cells’ MTs (Klupp et al., 2002). These complexes were further associated with nucleocapsids, 
which were found accumulating together at the nuclear surface (Kalejta, 2008). 
pp71, a component of the tegument, initiates viral IE gene expression through interaction 
with proteins that bind the nuclear components known as the promyelocytic leukemia 
(PML) nuclear bodies. The PML nuclear bodies’ mode of action is not fully understood and it 
is not clear whether they are pro- or anti-viral. It is however known that the viral genome 
binds to a subset of these PML nuclear proteins on successful entry into the nucleus (Stinski 
and Petrik, 2008) and in turn interacts with two other proteins, Daxx and Sp100 (Tavalai et 
al., 2006). The Daxx protein causes repression of viral gene expression and interaction of 
pp71 with Daxx counteracts this repression leading to stimulation of IE expression (Cantrell 
and Bresnahan, 2005). 
The major IE genes (MIE), IE86 and IE72, play pivotal roles in driving acute replication of 
HCMV. Although not fully understood, the MIE proteins function as transactivators of early 
and late viral gene expression which occurs within the 6 to 24 hours post infection (hpi) 
window (Fields et al., 2007) and is then followed by viral DNA replication.  
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HCMV DNA synthesis initiates at the cis-acting origin of lytic replication (oriLyt), a sequence 
that is more than 2.4 kbp in length and is located within the UL genomic region. oriLyt is a 
bidirectional promoter with a complex structure consisting of repeat elements as well as 
transcription factor binding sites. The essential regions are the IE2-UL84 responsive 
promoter region and an RNA/DNA hybrid structure which is a substrate of the UL84 protein 
(Prichard et al., 1998, Pari, 2008, Anders et al., 1992). IE2 binds to the oriLyt promoter 
activation element, a 14-bp DNA motif within the oriLyt, and, in cooperation with UL84, 
activates this promoter. Through a mechanism not fully understood, this binding facilitates 
or triggers initiation of DNA synthesis via transcriptional activation (Xu et al., 2004). Other 
elements important for DNA replication include the DNA polymerase (UL54), primase and 
primase-associated factor (UL70 and UL102), helicase (UL105), p52/DNA processivity factor 
(UL44) and the single-stranded DNA-binding protein (UL157). These elements form the core 
replication machinery and are conserved in other herpes viruses. Four proteins encoded by 
the UL112-113 region via alternative splicing act as transcriptional enhancers and recruit the 
DNA processivity factor (UL44) to the pre-replication foci. The helicase-primase complex 
formed by UL105-UL102-UL70 unwinds the dsDNA which is then prevented from reforming 
into a double strand by the binding of the single stranded DNA binding protein (UL57). DNA 
polymerase then binds and replicates the DNA with UL44 maintaining its binding to the DNA 
template (Pari, 2008, Fields et al., 2007, Sarisky and Hayward, 1996, Park et al., 2006). 
The circularised HCMV genome is thought to replicate by a process that involves the 
formation of concatemeric molecules which are in turn cleaved into unit length genomes. 
Initially, genome inversion and maturation occurs in the nucleus with the inversion leading 
to the formation of the different genome isomers.  The mature DNA is then packaged into 
pre-formed B capsids with some tegument proteins such as UL56, UL89 and UL104 playing a 
role in the packing. DNA cleavage and packaging is directed by the highly conserved short 
sequences found near the genomic termini in all mammalian HVs known as the pac1 and 
pac2. Once packaged, the mature virions are then transported in vesicles via the Golgi 
apparatus to the cell surface until the successful egress from the cells through the exocytic 
pathway, a process that takes approximately two days from DNA synthesis (Fields et al., 
2007, Pari, 2008, Xu et al., 2004, Sarisky and Hayward, 1996). 
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1.3 Pathogenesis of HCMV 
HCMV infection has a widespread distribution with a variable seroprevalence of between 
50% and 90% depending on the socio-economic state of a population (Sinclair and Sissons, 
2006). HCMV establishes a systemic infection with major cells infected including fibroblast, 
epithelial and endothelial cells, but leukocytes, dendritic cells, monocytes/macrophages, 
brain and retinal neurones, gastrointestinal smooth muscle cells and hepatocytes, are also 
susceptible to infection (Sinzger and Jahn, 1996, Rossini et al., 2012). Individuals infected 
have a lifelong infection with episodes of reactivation. 
HCMV is transmitted through infected bodily fluids such as saliva, urine as well as cervical 
and seminal excretions during sexual intercourse. The virus can also be transmitted through 
the placenta from infected pregnant women to their unborn babies with breast milk also 
reported as a source of transmission. Recipients of blood transfusion, solid organ or 
hematopoietic stem cell transplantation (HCT) from infected donors also risk HCMV 
infection (Fields et al., 2007, Dworsky et al., 1983, Gandhi and Khanna, 2004). Primary 
infection in immunocompetent individuals does not often manifest into clinically obvious 
disease, mainly as a result of the broad, strong and durable immune response detailed in 
the following section. 
1.3.1 Immune Response to HCMV 
HCMV infection triggers a coordinated innate and adaptive immune response. Microarray 
studies by Boehme et al. (2004) demonstrated that cells treated with a recombinant form of 
the envelope protein gB and with HCMV displayed a profile with a high degree of similarity 
with both treatments resulting in beta interferon secretion from fibroblast cells. This led to 
the conclusion that envelope glycoproteins represent at least one mechanism by which 
HCMV can elicit interferon responses and established that an antiviral state begins before 
the cell is infected. But interferon secretion is just one way in which the innate immune 
system responds. A viral attack also triggers an increase in the production of chemokines, 
cytokines and natural killer (NK) cells (Boehme et al., 2004). 
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T-lymphocytes and antigen-presenting cells cooperate and provide an adaptive immune 
response in an effort to counter the viral infection. The T helper (CD4+) cells recognise and 
interact with antigens presented on the cell surface by the major histocompatibility complex 
(MHC) class II molecules on the surfaces on infected cells eliciting their metabolic 
transformation which, in turn, release various cytokines. This leads to the activation of 
cytotoxic T lymphocyte (CTL) (CD8+) cells and macrophage cells. CTLs target infected cells 
and release cytotoxins that lead to cell death, preventing the spread of the virus. Similarly, 
macrophages prevent the spread of infection by targeting and phagocytosing infected cells. 
The CTLs can also recognise HCMV infected cells by directly interacting with the antigen 
presenting MHC class 1 molecules on infected cells leading to cytotoxin release (Fields et al., 
2007, Kindt et al., 2007). Unlike T-lymphocytes, NK cells lack the antigen-specific receptors 
but are able to employ NK-cell receptors that have the ability to distinguish abnormalities 
such as MHC class I expression or different profile of surface antigens displayed by the virus 
infected cells. Stimulation of NK cells can also be achieved by direct activation of natural 
killer cell protein group 2 (NKG2D) and Ly49H receptors by cytokines such as interleukins (IL) 
12 and 18 as well as INFs (Kindt et al., 2007, Arase and Lanier, 2004). NK cells present the 
body with an innate immune response to HCMV infection and their activation results in 
cytotoxicity or cytokine production, depletion of infected cells and prevention of virus 
spread. In addition to this, there are some viral proteins, IE and E, that induce apoptosis of 
the host cell.  For example US28 was shown to induce apoptosis through the activation of 
caspases 8 and 10 (Pleskoff et al., 2005), ultimately preventing replication and spread of the 
virus. 
HCMV, like all herpes viruses, has evolved mechanisms to counteract these events to 
promote a persistent and latent infection despite a robust and fully functional immune 
system.  
1.3.2 Latency 
Latency, as a characteristic of all herpes viruses, is defined by a reversibly quiescent state in 
which viral genomes are maintained, but viral gene expression is highly restricted and no 
virus is produced (Goodrum et al., 2012). Viruses are however able to reactivate and 
replicate, mostly when the host’s T-cell mediated immunity is weak, for example in AIDS 
 
10 
Stephen M Chiweshe (s1161257) CRAC 
patients or in solid organ and haematopoietic stem cells (HSC) recipients with a suppressed 
immunity. Viral replication and reactivation has also been linked to the differentiation and 
activation state of myeloid cells (Reeves et al., 2005). It is not fully understood how herpes 
viruses maintain latent and lifelong infection in immunocompetant hosts. Studies on HCMV 
latency are further complicated by the species specificity of this virus meaning that animal 
model studies have not been possible to date. Cell culture studies have however given some 
insight on the subject.  
Trying to understand mechanisms underlying the latency of HCMV has led to different lines 
of enquiry such as site(s) of latency, the viral genes involved in the maintenance of latency 
and successful evasion of the host’s immune system. Taylor-Wiedeman and colleagues 
studied peripheral blood mononuclear (PBM) cells from healthy seronegative and 
seropositive individuals. They used PCR to study PBM cells that were highly purified by 
fluorescence-activated cell sorting (FACS) and detected the presence of HCMV DNA 
primarily in monocytes (Taylorwiedeman et al., 1991).   
The presence of HCMV genome in the bone marrow CD34+ progenitor cells in the absence 
of a lytic gene expression led to the understanding that these cells are a possible site of 
HCMV latency. Work by Reeves and colleagues also demonstrated, in vitro, that myeloid 
dendritic progenitors are a site for HCMV latency and that their differentiation results in the 
reactivation of the virus’ lytic replication. They isolated and purified monocytes and CD34+ 
cells from HCMV seropositive and seronegative donors and analysed for the presence of the 
viral genome. Their results showed the presence of the viral genome in both the 
seropositive acquired monocytes and CD34+ cells, and that their differentiation to mature 
dendritic cells (DCs) led to the induction of lytic replication and an increase in the viral 
genome copy number (Reeves et al., 2005, Mendelson et al., 1996). Healthy seropositive 
blood donors can transmit HCMV infection to seronegative recipients and this transmission 
can be reduced by using leukocyte-depleted blood products (Sinclair and Sissons, 2006), 
supporting the understanding that HSCs harbour the latent HCMV genome and constantly 
shed the viruses as they differentiate into leukocytes. 
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In vitro studies have also identified a number of HCMV genes potentially associated with 
viral latency. These include the UL111A, UL81-82 antisense transcript (UL81-82ast), US28 
and miRNAs. 
The UL111A encodes for the cmvIL-10 protein, a homologue of human interleukin 10 (IL10). 
IL-10 is a cytokine that inhibits immune responses and the ability of HCMV to express a 
homologue of this cytokine suggest one of the ways the virus manages to avoid host 
immunosurveillance as it maintains latency in the host. cmvIL-10 has been reported to 
suppress the production of pro-inflammatory cytokines as well as the expression of the MHC 
II expression in CD34+ HPCs promoting viral latency (Goodrum et al., 2012, Sinclair and 
Sissons, 2006).  
The UL81-82 locus encodes for a 133 amino acid protein (16KD) that has been termed latent 
undefined nuclear antigen (LUNA). LUNA is understood to restrict the expression of the 
tegument protein pp71, a product of the viral gene UL82. pp71 is a transcriptional activator 
of the MIE promoter and suppression of pp71 by LUNA effectively inhibits the lytic 
replication of the virus, therefore promoting HCMV latency (Bego et al., 2005). Various 
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1.4 miRNA Studies & Identification 
1.4.1 General miRNAs Introduction  
MicroRNAs are small, single stranded RNA molecules of approximately 20 to 24 nucleotides 
in length. These non-coding RNAs are involved in the regulation of gene expression in 
eukaryotes thorough a post-transcriptional mechanism using the RNA silencing induced 
complex (RISC). Ambros and colleagues in 1993 discovered the first miRNA in Caenorhabditis 
elegans. Their studies revealed two lin-4 transcripts of 22 and 61 nucleotides; the 22 
nucleotide transcript being the result of the processing of the 61 nucleotide transcript. 
These transcripts contained sequences complementary to a repeated sequence element in 
the 3’ UTR of lin-14 mRNA and it was demonstrated that the lin-4 regulates lin-14 via an 
antisense RNA-RNA interaction leading to a decrease in the translation of lin-14 mRNA (Lee 
et al., 1993). This led to the birth of a unique new family of RNAs known as the miRNAs 
which have now been found to be ubiquitously expressed in metazoans (Grundhoff and 
Sullivan, 2011). miRNAs have since been established as a subject of enormous interest with 
their regulatory roles having been detected in various and diverse cellular processes such as 
immune function, apoptosis, tumorigenesis , growth, proliferation, phenotype, cell cycle as 
well as death, and in turn having a major influence on pathophysiological outcomes (Bhatt 
et al., 2011). 
1.4.2 miRNA Biogenesis & Function 
miRNAs are produced by gene transcription followed by sequential processing or editing. 
miRNA coding genes form independent transcription units and are found mainly between 
protein coding regions, intergenic, or in an antisense orientation of annotated genes. The 
few that are found within genes are located within introns. Most miRNA genes are 
transcribed by the RNA polymerase II (pol II) with a minority transcribed via RNA pol III 
(Grundhoff and Sullivan, 2011, Bhatt et al., 2011, Lee et al., 2004). 
Transcription of miRNA genes generates large transcripts of several kilobases in length 
known as primary miRNA (pri-miRNA) molecules which contain well-defined hairpin 
structures. These hairpin structures are recognised by a nuclear multi-protein complex, the 
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microprocessor. The microprocessor initiates the first of several steps, in processing of the 
transcripts, leading to the formation of a mature and functional miRNA molecule of 
approximately 20 to 24 nucleotides in length (Bhatt et al., 2011, Kim et al., 2009) (figure 
1.3). 
 
Figure 1.3: miRNA biogenesis (Winter et al., 2009)  
The Microprocessor complex consists of two main proteins, an RNase III-like protein known 
as DROSHA and its co-factor DiGeorge syndrome critical region 8 (DGCR8). The recognition 
and interaction of the hairpin structure by DGCR8 leads to the recruitment of DROSHA 
which in turn cleaves the pri-miRNA precisely at the stem loop structure generating a 
secondary miRNA precursor molecule of approximately 70 nucleotides, known as the 
precursor miRNA (pre-miRNA) (Bartel, 2004). 
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The protein exportin-5, which is a nuclear transport receptor family member, recognises the 
stem-loop structure of the pre-miRNAs and transports them from the nucleus to the 
cytoplasm where they are further cleaved by an RNase III enzyme known as Dicer, which 
removes the terminal loop structure generating a mature, double stranded miRNA (Yi et al., 
2003). One strand of the duplex is incorporated into the RNA Induced Silencing Complex 
(RISC), forming a stable interaction with the Argonaute 2 (Ago-2) protein of the RISC. Upon 
incorporation of the miRNA into RISC, it directs the complex to the target via the seed 
sequence, which is found between nucleotides 1 to 8 on the 5’ end of the miRNA and binds 
to the 3’ UTR of the target gene. Perfect complementarity of the miRNA to its target results 
in the cleavage of the mRNA whereas a partial match leads to translational repression (Hock 
and Meister, 2008, Grundhoff and Sullivan, 2011). It must, however, be noted that partial 
complementarity can lead to degradation of mRNA as well. A single miRNA can bind to and 
regulate different mRNA target sequences and in the same way, multiple miRNAs can bind 
and regulate the same target (Lee et al., 2004). 
1.4.3 Viral microRNAs 
With some of the smallest genomes and miRNA genes taking up relatively little genomic 
space, miRNAs offers viruses an efficient and convenient way of regulating both their own 
genomes as well as that of the hosts’ to support their life cycle (Dunn et al., 2005, Pfeffer et 
al., 2004). miRNAs also have the added advantages that a single miRNA can potentially have 
more than one target and that they do not elicit an immune response from the host 
(Grundhoff and Sullivan, 2011). 
The first viral miRNAs were discovered by Pfeffer and colleagues in 2004, expressed by EBV, 
a member of the γ herpesvirus sub-family (Grundhoff and Sullivan, 2011, Pfeffer et al., 
2004). After cloning small RNAs from a Burkitt’s lymphona cell line latently infected with 
EBV, genomic sequence analysis idenfied 5 miRNAS encoded by EBV (Pfeffer et al., 2004). 
Further studies have led to the discovery of more viral expressed miRNAs by different 
viruses. Interestingly, herpes virus encoded miRNAs make up more than 95% of viral 
miRNAs known to date with 6 of the 8 HHVs having been shown to expresss miRNAs 
(Grundhoff and Sullivan, 2011, Tuddenham and Pfeffer, 2011, Tuddenham et al., 2012). 
Enormous interest was raised as it emerged that this class of RNAs play a key role in 
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enhancing and regulating the herpes virus life cycle, both during lytic replication and 
latency.  
1.4.3.1 miRNAs in the context of HCMV 
There are 22 known and annotated HCMV encoded microRNAs (miRNA) and there is still 
potential for more to be identified. Pfeffer and colleagues first identified HCMV miRNAs in 
cells undergoing lytic infection. Using small RNA cloning and sequencing they identified nine 
precursor HCMV miRNAs which gave rise to a total of eleven mature miRNAs (Pfeffer et al., 
2005). Three of these miRNAs were also detected by Dunn and colleagues by cloning and 
sequencing techniques (Dunn et al., 2005). 
In 2005 Grey et al. used a bioinformatics approach directly comparing HCMV to the closely 
related Chimpanzee CMV (CCMV) to predict thirteen pre-miRNAs. A bioinformatics program 
called Stem-loop Finder (SLF; Combimatrix) was initially used to predict potential stem-loop 
secondary structures forming RNA transcripts from the HCMV genome. The results were 
further refined using a second algorithm called, MiRscan. MiRscan compares potential 
candidates from two sequences on the basis of evolutionary conservation of the miRNAs  
and was used to analyse the HCMV stem-loop transcripts with the CCMV genome for 
potential homology (Grey et al., 2005). The researchers identified five miRNAs, three of 
which were previously identified by Pfeffer et al. and two novel miRNAs, miR-US4-1 and 
miR-UL70-1. Using Northern blot analysis, they validated all five miRNAs as well as four 
previously identified by Pfeffer and colleagues (Grey et al., 2005). The development of high 
throughput sequencing techniques such as deep sequencing has allowed for the in depth 
studies of transcript populations. This effectively allows for the yielding a greater 
representation of a sample or assay as deep sequencing generates reads with a magnitude 
of millions as opposed to the hundreds that are achieved by small scale sequencing. Stark et 
al. successfully implemented the deep sequencing technique on small RNAs from HCMV 
lytically infected human fibroblasts cells. They validated ten previously identified pre-
miRNAs as well as two novel pre-miRNAs. All but two of these twelve pre-miRNAs resulted 
in two individual miRNA species leading to the generation of twenty two mature miRNAs 
(Stark et al., 2012). Their results did not detect the previously annotated pre-mir-UL70 but 
did reveal the presence of small RNAs outside the annotated HCMV miRNA regions. Further 
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studies on these regions by bioinformatics using the miResque miRNA prediction algorithm 
led to the discovery of two novel pre-miRNAs, pre-miR-US22 and pre-miR-US33as, which 
were validated by Northern blot analysis (Stark et al., 2012). The HCMV encoded miRNAs 
are summarised in table 1.2. Recently Meshesha et al. identified two further pre-miRNAs, 
pre-miR-UL59 and pre-miR-US29, using deep sequencing. They confirmed both pre-miRNAs 
by qPCR and proposed that both pre-miRNAs form two mature miRNA. They also detected 
the formation of one more miRNA, miR-US4-3p, from an already identified pre-miRNA and 
this potentially brings the total of known HCMV encoded miRNA to twenty seven. 
Interestingly their results did not reveal any reads for pre-Mir-UL70, agreeing with previous 
studies by Stark and colleagues. 
 
Fig1.4 HCMV miRNA gene map (Meshesha et al., 2012). Also confirmed is the US33as which 
is not included. Although included, UL70 has been shown to not code miRNAs. 
  
1.4.3.2 HCMV miRNA Potential Targets/Functions - Latency 
The three miRNAs, miR-US25-1, miR-US25-2 and miR-UL112-1, have been shown to regulate 
viral and/or cellular genes in such a way that may promote HCMV latency. Work by Grey et 
al. demonstrated that miR-UL112-1 targets the viral gene IE72 (IE1) that encodes a major 
trans-activating protein. Due to its ability to drive acute replication of HCMV, IE72 along 
 
17 
Stephen M Chiweshe (s1161257) CRAC 
with IE86, have been suggested to play pivotal roles in establishment and reactivation of the 
virus. Its inhibition may promote latency (Grey et al., 2007). miR-US25-1 and 2 have been 
demonstrated by studies from Stern-Ginossar and colleagues to target host cellular 
transcripts in a mechanism that  reduce viral DNA synthesis. By ectopically expressing these 
miRNAs in HEK293 cells and infecting them with other viruses e.g. HSV 1, they confirmed 
that these miRNAs were regulating cellular transcript(s) rather than the viral genome as 
they exhibited the same effect on the growth of these viruses (Stern-Ginossar et al., 2009). 
On-going work in our lab is trying to establish the role of mir-US25 miRNAs in regulating the 
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Table 1.2: Known HCMV miRNAs to date. 
Annotation and Name Representative Sequence1 Genome Position (5’to 3’) 2 
Annotated in miRBase From  To 
miR-UL112-3p AAGTGACGGTGAGATCCAGGCT 164557 164578 
miR-UL148D TCGTCCTCCCCTTCTTCACCGT 193587 193607 
miR-UL22A-5p CTAACTAGCCTTCCCGTGAGA 27992 28011 
miR-UL22A-3p TCACCAGAATGCTAGTTTGTAG 28029 28050 
miR-UL36-5p TCGTTGAAGACACCTGGAAAGA 49914 49893 
miR-UL36-3p TTTCCAGGTGTTTTCAACGTG 49870 49851 
miR-US25-1-5p AACCGCTCAGTGGCTCGGACCG 221539 221519 
miR-US25-1-3p GTCCGAACGCTAGGTCGGTTCT 221496 221476 
miR-US25-2-3p ATCCACTTGGAGAGCTCCCGCGGT 221702 221680 
miR-US25-2-5p AGCGGTCTGTTCAGGTGGATGA 221760 221739 
miR-US33-3p TCACGGTCCGAGCACATCCAA 226731 226712 
miR-US33-5p ATTGTGCCCGGACCGTGGGCGC 226768 226750 
miR-US4-5p TGGACGTGCAGGGGGATGTCTG 201376 201395 
miR-US5-1 TGACAAGCCTGACGAGAGCGT 202317 202337 
miR-US5-2-3p TTATGATAGGTGTGACGATGTC 202444 202465 
Not annotated in miRBase 
miR-UL112-5p CCTCCGGATCACATGGTTACTCAG 164520 164540 
miR-US4-3p TGACAGCCCGCTACACCTCTCT 201416 201434 
miR-US5-2-5p CTTTCGCCACACCTATCCTGAAAG 202408 202429 
miR-US22-5p TGTTTCAGCGTGTGTCCGCGGGC 216157 216177 
miR-US22-3p TCGCCGGCCGCGCTGTAACCAGG 216195 216216 
miR-US33as-5p TGGATGTGCTCGGACCGTGACG   
miR-US33as-3p CCCACGGTCCGGGCACAATCAA   
Table details obtained from (Meshesha et al., 2012, Stark et al., 2012). 1Representative 
sequence was picked as one with the highest reads in the deep-sequencing. 2The positions 
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1.4.4 Techniques for Identifying miRNA Targets 
By identifying viral miRNA targets, we can increase our understanding of their roles and how 
they influence the viral life cycle. Different tools and techniques have been used to study 
miRNAs and seeking to improve these will further elucidate miRNA characteristics, targets 
and function. The techniques previously used, as described below, include bioinformatic 
studies, microarray analysis, RISC immunoprecipitation, High-Throughput Sequencing of 
RNAs isolated by Cross-Linking Immunoprecipitation (HITS-CLIP) and Photoactivatable-
Ribonuclease enhanced Cross-Linking and Immunoprecipitation (PAR-CLIP). We adopted a 
recently developed technique, Cross-Linking and Analysis of cDNA (CRAC), to study the 
targets of the HCMV miR-US25 cluster encoded miRNAs. 
1.4.4.1 Bioinformatic Studies 
Bioinformatics is defined as the application of computational techniques to understand and 
organise the information associated with biological macromolecules. Bioinformatics is in 
many ways an ideal approach because of the ease with which computers can handle large 
quantities of data and probe complex dynamics observed in nature (Luscombe et al., 2001). 
Bioinformatics equips researchers with a starting point as it identifies potential candidate 
genes, narrowing down the area and focus point for biochemical studies. A bioinformatics 
study is mainly a predictive tool with variable limitations depending on the parameters set 
for the algorithm. There has to be a fine balance in setting up the algorithm parameters in 
such a way that the stringency levels do not miss out potential targets while at same time 
minimising the generation of false positives. Further verification steps are taken by the use 
of wet-bench experimental techniques such as luciferase assays, cloning and sequencing 
and microarray studies. Bioinformatics remains a strong tool for miRNA studies and can also 
be used as a validating tool for targets identified by other biochemical techniques. 
An example of an algorithm that has been used to identify miRNA targets is RepTar, 
developed by Stern-Ginossar and colleagues. RepTar was used to identify potential human 
target genes of miR-UL112-1, a HCMV miRNA. The algorithm searched for repetitive 
elements in each 3’UTR on the basis that miRNA binding sites can repeat several times in 
the target’s 3’ UTR. These studies identified the major histocompatibility complex class 1-
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related chain B (MICB) gene as a top candidate target for HCMV-miR-UL112-1 (Stern-
Ginossar et al., 2007).  
Grey et al. (2007) reported the use of a comparative bioinformatics approach to identify 
viral targets of miR-UL112-1. Using an online target identification algorithm RNAhybrid, they 
identified 32 potential targets for miR-UL112-1 from 37 HCMV ORFs. However, by 
comparing these results to the potential targets of the closely related chimpanzee 
cytomegalovirus (CCMV), 14 genes were predicted to be targeted by miR-UL112-1 in both 
CCMV and HCMV genomes. Target sites for miR-UL112-1 were confirmed in three viral 
genes, IE72, UL120/121 and UL112/113 and later validated using luciferase assays and 
western blot analysis (Grey et al., 2007). 
These studies demonstrate that bioinformatic methods can play an important role in target 
identification and further studies may elucidate future discoveries on viral miRNA function. 
1.4.4.2 Microarray Studies 
Microarray studies provide a valuable tool for studying and identifying miRNA targets based 
on gene expression profiling and its ability to simultaneously establish the activity of a large 
number of genes. Microarrays are used for their ability to identify transcripts subjected to 
degradation as a result of being targeted by miRNAs of interest (Lim et al., 2005).  
In microarray assays, DNA probes on a microchip are used to detect the presence of a 
transcript by hybridisation, and the amount of mRNA bound to each site on the array 
indicates the expression level of the coding gene. Typically, the levels of transcripts are 
compared between a cell line transfected with a miRNA of interest and a control cell line 
usually transfected with an empty vector. miRNA targeted transcripts will therefore be 
expected to show a reduction of expression due to cleavage when compared to the negative 
control sample. This provides an effective way of identifying miRNA targets particularly for 
plants as they exhibit perfect complementarity with their target, primarily resulting in the 
cleavage of the transcript whereas with viral and animal miRNAs, the level of degradation is 
very low as mentioned in section 1.4.2. This makes the detection of transcript level variation 
difficult with small changes as low as 2- fold having been previously reported (Ziegelbauer et 
al., 2009).  
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Lim and colleagues used the microarray technique to demonstrate the tissue specific 
expression of the human miRNAs miR-1 and miR-124. By transfecting HeLa cells with miR-
124 RNA duplexes of the miRNAs, the expression profile shifted towards that of the brain 
where the miRNA is usually expressed. The same was noted for miR-1 with the expression 
profile shifting towards that of the heart and skeletal muscle where it is usually expressed. 
Microarray has also been used in the identification of cellular genes targeted by KSHV-
encoded miRNAs (Lim et al., 2005). Samols and colleagues transfected HEK293 cells with a 
plasmid encoding ten KSHV miRNAs or an empty vector for control samples. They isolated 
the RNA from the cell lines and generated cDNA for microarray profiling. Their results 
showed an alteration in the expression of eighty one genes with eight of these having a 
decrease greater than 4-fold. These were investigated further by qRT-PCR, bioinformatics 
and luciferase assays with the final results confirming the KSHV miRNA dependent inhibition 
of the 3’ UTRs of the SPP1 (osteopontin), PRG1 (plasticity related gene 1) and THBS1 
(thrombospondin 1) genes as well as the targeting of the THBS1 by multiple KSHV miRNAs 
with the major miRNA species being miR-k12-1, miR-k12-3-3p, miR-k12-6-3p and miR-k12-
11 (Samols et al., 2007).  
Microarray studies, in combination with deep sequencing and luciferase assay analysis by 
Suffert et al. (2007) led to the identification that three KSHV miRNAs, miR-K12-1, miR-K12-3 
and miR-K12-4-3p target caspase 3, an effector caspase involved in apoptosis control.  These 
studies, conducted in B lymphocyte DG-75 and endothelial EA.hy296 cell lines, 
demonstrated the down-regulation of transcripts with 3’ UTRs that possessed KSHV miRNA 
seed-matches. Deep sequencing of cell lines transfected with KSHV miRNA clusters were 
used to determine the relative abundance of miRNA within the cluster and determine 
transcripts with a seed-sequence match within their 3’ UTRs. Transcripts showing decreased 
expression were validated as miRNA targets by luciferase assays (Suffert et al., 2011). 
It is fair to say, therefore, that microarray studies provide a solid starting point to identify 
potential targets which can be investigated further by detailed analyses. However, there is a 
potential loss of valid targets which would appear as false negatives, for example as result of 
expression at the RNA level not being altered due to miRNA binding and also those that are 
affected or down-regulated through secondary effects would score as false positives 
(Karginov et al., 2007). As a result, microarray usage has been combined with other tests 
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such as qRT-PCR and luciferase assays to validate the results as well as a validating tool 
when used in combination with other miRNA studies techniques such as bioinformatics and 
RISC-IP.   
1.4.4.3 RISC Immunoprecipitation 
RISC Immunoprecipitation (RISC-IP) is a biochemical technique for isolating miRNA targeted 
transcripts relying on immunoprecipitation (IP) of the RISC complex. Cell lines stably 
expressing a tagged component of the RISC complex, Ago-2, allow for the IP of these 
complexes and the transcripts can then be identified by microarray analysis. The Ago-2 
protein is tagged with a c-myc epitope and antibodies conjugated to agarose beads are used 
to isolate these complexes by IP (Grey et al., 2010, Karginov et al., 2007, Dolken et al., 
2010). After transfecting a cell line stably expressing this tagged version of the Ago-2 protein 
with the miRNA of interest in the form of a plasmid, a sample of the lysate is taken for 
quantification of RNA levels, which represents the total fraction. IP is then conducted and 
the RNA from the IP complexes are quantified by microarray or quantitative PCR analysis. 
On the basis that the association of a specific mRNA with the RISC complex is represented 
by quantitative enrichment of the mRNA in the IP fraction relative to the total (pre-IP) 
fraction, the miRNA target is determined from the microarray analysis data (Grey et al., 
2010). The cell line can also be infected by a virus and by comparing the IP fraction of 
uninfected cells to those of infected cells the viral miRNA targets can be identified. The 
uninfected IP fraction analysis will identify the host’s miRNA target and the infected fraction 
will identify the viral miRNA targets in addition to the host’s target. The specific viral miRNAs 
will therefore have a different enrichment profile which allows their identification. The RISC-
IP procedure is schematically represented in figure 1.5. 
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Figure 1.5: A schematic representation of the RISC-IP procedure (Courtesy of Dr Reynolds 
and Jon Pavelin). (A) miRNAs of interest are transfected into a cell line expressing a tagged  
Ago-2 protein and an empty vector is used to generate an uninfected IP sample. The miRNAs 
are incorporated into the RISC, directing mRNA targeting via seed sequence 
complementarity. (B) Cells are lysed and an anti-Ago-2 antibody is used to pull down 
RISC/miRNA/target mRNA complex. (C) RNA is extracted from RISC and analysed, in this 
illustration by microarray but this can also be conducted by qRTPCR. 
 
The identification of multiple cell cycle genes, particularly cyclin E2, as targets of the HCMV 
encoded miR-US25-1 miRNA is an example among many of the successful implementation 
of RISC-IP (Grey et al., 2010).  
1.4.4.4 HITS-CLIP 
In 2005, Ule et al. developed the HITS-CLIP technique to identify protein-RNA interaction 
sites in living cells. The resulting technique reduces false positives that may occur with 
microarray or IP by the high stringency purification it allows due to the ultra violet (UV) 
radiation cross-linking of the RNA to proteins before IP. The cross-linking results in the 
formation of irreversible covalent bonds between the protein and the RNA molecules. An 
overview of the HITS-CLIP technique is shown in figure 1.6. In the procedure, a cell culture is 
transfected with a plasmid expressing the miRNA of interest or a vector expressing a 
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negative control miRNA. Cells are UV-irradiated on ice (b) followed by immunoprecipitation 
of the RISC complex using an antibody raised against the human Ago-2 protein (c/d). With 
the miRNA targeted transcript covalently bonded to the protein as well as the miRNA, the 
remaining parts of the mRNA is digested using an RNase enzyme (e). The RNA is then 
dephosphorylated, ligated to a 3’ RNA linker (f) and radioactively labelled by 5’ γ32P (g). The 
RISC complex is isolated by SDS-PAGE and the complexes are transferred to a nitrocellulose 
membrane (h). The membrane is then exposed to an X-ray film allowing for the mapping of 
the region of the membrane containing the RISC complex (h). After excision, the membrane 
is treated with proteinase K (i) which leads to the dissociation of the RNAs from the protein. 
A 5’ linker is then ligated to the RNA (j) followed by reverse transcription generating a cDNA 
library which is further amplified by PCR (k). The cDNA is then sequenced (l) and the reads 
correspond to the miRNA and mRNA originally bound to the RISC complex (Wilbert and Yeo, 
2011, Ule et al., 2005). 
 
Fig 1.6: Schematic representation of HITS-CLIP procedure (Wilbert and Yeo, 2011) 
Riley et al. (2012) successfully used HITS-CLIP technique to study EBV miRNA targets. Using a 
Jijoye Burkitt’s lymphona cell line, which expresses 43 of the 44 known EBV miRNAs, they 
identified 3 viral 3’UTRs and 1503 human 3’UTRs to be co-targetted by both EBV and cellular 
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miRNAs. 161 human 3’ UTRs were also found to be targeted by EBV miRNAs only (Riley et 
al., 2012). High throughput sequencing results from the HITS-CLIP assay showed that of the 
EBV miRNAs, 12 of them were highly expressed and represented 90% of the total EBV 
miRNA reads and these were selected for further detailed analysis. Analysis by 
bioinformatics revealed that the EBV early lytic cycle protein’s, BHRF1, 3’ UTR had miRNA 
binding sites for the human miR-142-3p and miR-17 family as well as the EBV BART-10-3p 
miRNA. Similarly, the latent membrane protein 1 (LMP1) had two dinstictive 3’UTR binding 
sites for human miR-17 family, EBV miRNAs BART-19-5p and BART-5-5p. These results were 
validated by luciferase assays. By using bioinformatics and focusing on the highly expressed 
EBV and human miRNAs, the same studies reaveled that the EBV and human miRNA co-
targeted mRNAs are most particularly involved in transcription, apoptosis and cell cycle 
pathways. EBV miRNAs targeted genes involved in transcription, apoptosis, Wnt signalling 
and cell cycle control (Riley et al., 2012). 
1.4.4.5 PAR-CLIP 
Tushl and colleagues modified the HITS-CLIP technique and developed PAR-CLIP. In this 
procedure, cells are incubated with a photoactivatable ribonucleoside4-thiouridine before 
the protein-RNA UV-crosslinking. This added step facilitates the identification of the exact 
cross-linked sites in the cDNA as the thymidine becomes cytidine in the sequenced cDNA 
(Hafner et al., 2010, Wilbert and Yeo, 2011). The additional step theoretically results in an 
improved cross-linking and the refinement of target sites as well as less background noise. 
An illustration of this procedure is shown in figure 1.7. 
PAR-CLIP technique has been successfully used to study miRNA targets for EBV and KSHV 
viruses. Using primary effusion B cell lines, Gottwein and colleagues revealed that KSHV 
miRNAs directly target more than 2000 cellular mRNAs and identified miR-K15 to be a mimic 
of the hematopoietic miRNA miR-142-3p. Their studies also confirmed the encoding of a 
miR-K11 and its mimicking properties of the hematopoietic miRNA miR-155. KSHV miRNA 
targets included transcriptional regulation, signal transduction, vesicular trafficking, and the 
regulation of cell cycle and apoptosis (Gottwein et al., 2011). However, in their report, they 
clarify that “it is important to point out that PAR-CLIP merely captures interactions, 
including those that may be transient or may not result in functionally relevant levels of 
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regulation” (Gottwein et al., 2011). Skalsky et al. (2012) investigated EBV miRNA targets 
using B-95-8 (EBV strain) infected lymphoblastoid cell lines (LCLs), an EBV model for latency 
studies. In their studies, they combined PAR-CLIP and bioinformatics to identify 531 EBV 
target sites in cellular 3’ UTRs and confirmed 24 of these by luciferase reporter assays. Their 
findings showed that EBV miRNAs mainly target cellular transcripts which are involved in 
innate immunity, cell survival and cell proliferation and do so during latent infection (Skalsky 
et al., 2012). 
 
Fig 1.7: Overview of the PAR-CLIP procedure (Corden, 2010). 
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The discussed bioinformatic and biochemical techniques have been effective in miRNA 
studies but they have limitations. Bioinformatics as mainly a prediction tool can generate 
false positives and targets can be missed as false negatives. RISC-IP is dependent on the 
enrichment of transcripts as well as the microarray analysis of transcripts which is limited by 
the pre-designed probes. HITS-CLIP and PAR-CLIP techniques offer an improved method to 
RISC-IP but they lack the definitive target identification. As a result, most of the miRNA 
targets and functions are unknown highlighting the need of more improved and effective 
techniques. In this thesis, CRAC, an improvement from the CLIP techniques is adopted and 
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Chapter 2: Materials and Methods 
2.1 Cell culture  
All cell lines were grown in Nunclon delta coated 175 cm2 flasks in Gibco® Dulbecco’s 
modified eagle medium (DMEM) supplemented with 10% heat-activated foetal bovine 
serum (FBS) and penicillin/streptomycin (0.5 Units/mL). 
2.2 Immortalised cell lines 
Human embryonic kidney (HEK) 293T cells were passaged 1:4 when confluent using 0.25% 
Trypsin-EDTA solution. A HEK293 cell line constitutively expressing Ago2 carrying a dual 
Protein A and His tag were created using the Invitrogen Flip-in™ system 
(http://biochem.dental.upenn.edu/GATEWAY/Vector_manual/flpinsystem_man.pdf). These 
cells were a generous gift from David Tollervey.  
2.3 Plasmid DNA 
pCMVUS25 was constructed by PCR amplifying a region from the HCMV genome encoding 
the miR-US25 miRNAs, US25-1, US25-2-3p and US25-2-5p using the primers listed below 
GCGGAATTCTACAACAGCGGATTCCC, ATAGCGGCCGCACGAGTGTCGTAGGCG. This region 
corresponds to nucleotide coordinates 214665 to 216130 of AD169 genome (accession 
number X17403.1). The PCR fragment was cloned into the EcoRI and NotI sites replacing the 
eGFP cassette of peGFP C1 (Clontech). Expression of all three miRNAs was confirmed by RT-
PCR analysis. In control transfections peGFP C1 (Clontech) or pSIREN (Clontech) were used. 
2.4 Optimisation Steps 
2.4.1 Transfection 
To study the targets of specific HCMV miRNAs, plasmid DNA expressing the miRNA of 
interest was introduced into the HEK293 cell line by transfection using Fugene HD™ 
(Promega). Six well plates were set up and different amounts of Fugene and plasmid DNA 
where checked. The ratios resulting in the best transfection levels were determined using 
fluorescent microscopy. A GFP plasmid (peGFP or pSIREN) was used for this procedure and 
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the Carl Zeiss Colibri Illumination System microscope used analyse transfection levels. Each 
well was seeded with 1 x 106 cells and transfected after 24 hrs with the amounts of Fugene 
and plasmid DNA detailed in table 2.1. 
Table 2.1: Fugene:DNA ratios used for transfection optimisation. 









The tagged Ago-2 protein expression is doxycycline inducible. To check successful induction 
and the amount of doxycycline required for induction varying amounts of doxycycline were 
used and the level of expression analysed by Western blotting. 5 hrs post transfection of a 
six well plate, 500mg/ml, 250mg/ml, 125mg/ml, 50mg/ml, 5mg/ml or 0mg/ml of 
doxycycline was added to a well. The cells were harvested 24 hrs from transfection using a 
gel 1 x loading dye and analysed for the presence of Ago-2 by western blotting. 
2.4.3 Dynabeads-IgG Conjugation & Lysate Concentration (Small Scale 
IP) 
To determine the effectiveness of Dynabeads conjugation by IgG antibodies and the effect 
of lysate concentration on the quality of immunoprecipitation a small scale IP was 
performed. Quantities representative of a 100 fold less, than those used for the CRAC assay, 
of the conjugated Dynabeads and lysate volume, 300µg of beads and 100µl of lysate, were 
used for the IP following the CRAC assay protocol up to RNase IT digestion exclusive. The 
conjugation of Dynabeads with IgG’s effectiveness was checked by comparing the quality of 
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IP to that of commercially obtained rabbit IgG conjugated agarose beads (Sigma).  Three 
different lysate concentrations were checked, and these were, as obtained from harvesting 
(100%) concentrated, 1 in 4 dilution of the harvested lysate (25%) and 1 in 10 dilution (10%). 
The complexes were eluted from the beads using a protein gel loading dye (x1) and these 
served as western blot samples. 
2.4.5 Western Blot Analysis 
15µl of each sample was loaded, run on 10% acrylamide gels (appendix 5.2.1.3) for 1.5 hrs at 
150 V using the Bio-Rad Mini-PROTEAN® Tetra system, and transferred onto a PVDF 
membrane (Millipore) by semi-dry transfer using the Bio-Rad Trans-Blot® Turbo™ Transfer 
system. Blocking of the membrane to minimise non-specific antibody binding was 
conducted using 5% milk powder (Marvel) in TBST solution (appendix 5.2.1.4).  Protein 
levels were detected using peroxidase-anti-peroxidase (PAP) from Sigma, an antibody 
specific for Ago-2 protein and do not require a primary antibody. The membrane was 
washed 3 times, 20 mins each time, using TBST buffer solution. ECL plus agent (Amersham) 
was used for the detection of protein presence following manufacturer’s guidelines and the 
membrane was visualised under UV using the FluorChem® HD2 gel box. 
2.5 Lysate production 
Four 15 cm dishes were used for lysate production per every miRNA of interest. 3 x 108 cells 
were seeded per dish and transfected with plasmid DNA after 24 hrs. 
2.5.1 Plasmid DNA Transfection and Induction 
Following the optimisation steps, 30µg of plasmid DNA was transfected per 15cm dish of 
70% confluent HEK-293 cells using 120µl of Fugene HD™ (Promega), as a carrier and 
Optimem media following the manufacturer’s guidelines. Tagged Ago2 expression was 
induced 5 hours post transfection using 500mg/ml of doxycycline. Supplemented DMEM 
was changed prior to transfection and also 24 hours post transfection. Transfection levels 
were checked using the Carl Zeiss Colibri Illumination System Microscope by checking for 
the green fluorescence on the pGFP transfected cells 24 hours post transfection. 
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2.5.2 UV Crosslinking and harvesting 
Each plate was washed with PBS and immediately UV cross-linked on ice using the UV 
Stratalinker 1800 at 400 mJ/cm2. Cells were lysed directly on the plate by adding 2.5 ml of 
cooled lysis buffer (see appendix section 5.2.4) and then scrapped off. The lysates were 
incubated on ice for 10 mins, centrifuged at 4500 rpm and 4oC to remove cell debris and 
stored at -80oC. 
2.6 IgG-Dynabeads Conjugation 
300mg of Dynabeads® M270 Epoxy from Invitrogen were conjugated using 3, 525µl (from a 
stock solution of 14mg/ml) of rabbit IgG from Sigma following the optimised and established 
protocol from Rout laboratory (http://commonfund.nih.gov/pdf/Conjugation-of-
Dynabeads.pdf). Preparation and recipes of the required buffers is detailed in appendix 
section 5.2.1.1 and the protocol followed in section 5.2.2. In summary, Dynabeads were 
washed 3 times using PBS and incubated with the IgG antibody mix at 30oC with gentle 
agitation for 18 to 24 hours.  Following incubation, conjugated Dynabeads were washed 
with glycine, Tris, Triethylamine and PBS prior to storing in PBS + 0.02% Sodium azide at 4oC. 
2.7 CRAC 
A detailed protocol of the steps, procedures and materials used for the CRAC is detailed in 
the appendix, section 5.2.3. Buffer recipes are shown in section 5.2.1.4. Where changes 
were made to the procedures or materials used, it has been detailed in the result section 
prior to the achieved results (chapter 4).  
Gel electrophoresis purification of the complexes following radioactive labelling was 
conducted on a NuPage 4-12% precast gel (10 well, product NP0335BOX, Invitrogen) using 
the Invitrogen™ Novex® Mini-Cell system. The complexes were transferred onto a PVDF 
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2.8 BLAST (Basic Local Alignment Tool) 
The link below was used for the analysis of the CRAC sequence results. The parameters: Human 
genomic + transcript and Highly similar sequences (megablast), were selected. 
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&BLAST_PROGRAMS=megaBlast&PAGE_TY
PE=BlastSearch&SHOW_DEFAULTS=on&LINK_LOC=blasthome 
2.9 Deep Sequencing 
The libraries were checked for their quality and quantity using the Agilent Bioanalyser DNA 1000 
chip(Agilent Technologies UK Ltd, Stockport, Cheshire) and the KAPA Illumina SYBR Universal Lib Q. 
Kit (Anachem Ltd, Luton Beds) respectively.  The libraries were pooled and the pool concentration 
was adjusted to 10nM for input to the Illumina Truseq cluster generation kit. The flow cell was 
prepared using the Illumina Truseq PE Cluster kit V3 (Illumina Ltd., Little Chesterford Essex) following 
the manufacturer’s recommendations. The library pool was loaded onto the flow cell at a final 
concentration of 9pM using the Illumina cBOT instrument. The sequencing, 100 cycles single end, 
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Chapter 3: RESULTS 
3.1 Introduction  
A total of 27 HCMV encoded miRNAs has been reported, but the targets and functions of 
only a few are known. Identifying these miRNAs target transcripts and studying their 
functions would elucidate why these transcripts are targeted and help us understand the 
miRNAs functions. As previously mentioned, studies in the Grey laboratory have used a 
combination of bioinformatics and biochemical techniques to identify targets of two HCMV 
miRNAs, miR-UL112-1 and miR-US25-1. However, these techniques have limitations to their 
effectiveness.  Therefore there is need for additional technologies for the identification of 
novel miRNA targets. The aim of this project is to optimise and establish a newly developed 
technique for miRNA studies, the CRAC assay. CRAC is a cutting edge technique with the 
ability of identifying a miRNA and its target sequence enabling us to unravel and understand 
the science behind HCMV miRNA functions. 
CRAC follows a similar procedure to that outlined in the HITS-CLIP technique (figure 1.6) 
with two additional modifications aimed at improving the immunoprecipitation (IP) quality 
and target transcript identification. The first modification is the double tagging of the Ago-2 
protein, as represented in figure 3.1, allowing for a two-step affinity purification. The Ago-2 
protein is N-terminally tagged with protein A and histidine tags. The protein-A tag and 
histidine tag (his-tag) binds to the IgG antibodies and nickel beads respectively. 
 
Fig 3.1: Double tagged Ago-2 protein. Six histidine molecules form the his-tag, represented 
in brown, which is attached to the N-terminal of Ago-2 protein on one end and a protein A 
tag in black, on the other end. 
 
In addition, an intramolecular-ligation step has been introduced which ligates the end of the 
RISC associated miRNA to the associated target mRNA resulting in the formation of a 
miRNA-mRNA hybrid. Sequencing of the hybrid RNA would therefore reveal both the 
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targeted mRNA and the targeting miRNA. Here I will give more details and illustrate in 
figures the step by step procedure of the CRAC assay but the figure will focus on the Ago-2 
protein and it is worth noting that this is part of the RISC. 
3.1.1 UV Crosslinking 
The tagged Ago-2 expressing cells are UV irradiated to enable the crosslinking of the RNAs 
with proteins. This results in the establishment of the stable and irreversible covalent 
bonding between the RNAs and the proteins. It has been reported that the covalent bonds 
form between the nucleic acid pyrimidine bases and specific amino acids such as lysine, 
cysteine, phenylalanine, tryptophan and tyrosine with the RNA-protein complexes needing 
to be in direct contact (approximately over single angstrom distances) (Budowsky et al., 
1976, Chi et al., 2009, Ule et al., 2005). 
 
Fig 3.2: UV Crosslinking. A target transcript bound to the miRNA is UV irradiated leading to 
the formation of covalent bonds between the RNAs and the Ago-2 protein represented as 
red crosses. 
 
This step allows for stringent purification conditions such as the high salt and denaturing 
washes conducted throughout the assay while conserving the binding of the miRNA to the 
target transcript. 
3.1.2 Protein A-tag mediated IP-RNase Digestion- His-tag mediated IP 
IgG antibody (IgG Abs) conjugated Dynabeads are used for the first IP with the IgG Abs 
binding to the protein A tag of the Ago-2 protein, Fig 3.3 (a). A magnet is the then used to 
isolate the IgG bound complexes from the solution followed by low and high salt buffer 
washes of the IP to eliminate non-specific binding. Limiting RNAse digestion is then 
conducted to remove the overhanging transcripts leaving the RISC incorporated mRNA 
which corresponds to the miRNA target (b). A guanidine rich buffer, which causes protein 
denaturing, is used to elute the complexes from the IgG conjugated Dynabeads. A second IP 
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is performed using nickel beads that bind to the His-tag of the Ago-2 protein (c). With the 
complexes still immobilised on the nickel beads, an intra-molecular ligation reaction, 
resulting in the formation of a hybrid between the miRNA and the mRNA, is performed 
using a T4 RNA Ligase 1 enzyme (d). T4 RNA Ligase 1 is a single stranded RNA ligase that 
catalyses the formation of a phosphodiester bond, through ATP hydrolysis, between a 5’ 
phosphoryl-terminated nucleic acid acting as a donor with a 3’ hydroxyl-terminated nucleic 
acid acceptor.  
 
Fig 3.3: Modified steps of CRAC.  (a) First pull down using the IgG antibody targeting the 
Protein A tag, (b) Second pull down using the nickel beads that target the His-tag, (c) Intra-
molecular ligation step generating a RNA-miRNA hybrid.  
 
A 3’ linker of known sequence is ligated with the complex still immobilised on the nickel 
beads. This reaction is catalysed by a truncated K227Q T4 RNA Ligase 2 enzyme, a point 
mutant of T4 RNA ligase 2 that ligates pre-adenylated 5’ end of DNA or RNA to a 3’ hydroxyl 
end of RNA without the need of ATP. T4 RNA Ligase 2 mutation reduces the formation of 
undesired ligation products such as concatemers and circular products. Following ligation 
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Fig 3.4: Representation of the Intra-molecular ligation reaction and radioactive labelling.  
(A) - represents the possible outcomes of intra-molecular ligation where a mixed population 
of non-ligated (left panel) and ligated shown with blue linker (right panel) is generated. 3’ 
Linker is shown as a green line. (B) - represents the radioactive labelling of the 5’ ends ( ).      
 
An imidazole containing buffer is used to elute the complexes from the nickel beads via 
competitive binding to the His-tag. Following elution, the same steps, as detailed in the PAR-
CLIP technique from (h) to (l), are performed. These include SDS polyacrylamide gel 
purification of the complexes after radioactive labelling followed by transfer to a membrane 
and extraction of the RNA by proteinase K digestion. Proteinase K fragments the proteins 
leading to the release of miRNAs and target transcripts. A 5’ linker of known sequence is 
then ligated to the IP products using T4 RNA ligase 1. The 5’ linker contains an additional 
known variable sequence referred to as a barcode. Ligation of 5’ linker oligonucleotides with 
different barcode sequences allows for subsequence multiplexing of deep sequence 
reactions. The 3’ and 5’ linkers allows for the amplification of final cDNA CRAC product with 
primers designed to match linkers of known sequence. The PCR primers have additional 
nucleotides that create overhanging known sequences referred to as adapters. Adapters are 
used in deep sequencing to bind the immobilised solid support chip oligos for cluster 
generation as explained below. A typical cDNA fragment from a CRAC assay, including its 
features, is illustrated in figure 3.5. 
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Fig 3.5: An example of a cDNA fragment for deep sequencing. PCR primers are underlined, 
5’Linker highlighted, 3’ Linker highlighted, Bar code in italics and the RNA insert is shown in 
bold. Non-highlighted and underlined sequences represent the adapters from PRC primers.
  
The deep sequencing procedure is best partitioned into three steps, library preparation, 
cluster generation and sequencing. The cDNA library is prepared for deep sequencing by 
purification and size selection of fragments with 200 to 300 base pairs. Clusters are then 
generated by isothermal amplification of single molecules in a flow cell on a solid support 
chip cluster system. The chip is densely coated with a network of oligos on its surface that 
binds to the fragments’ ligated adapters. Successfully bound oligos are extended, creating 
copies that are covalently bound to the flow cell surface. Clonal amplification through a 
series of extension and bridge amplification leads to the generation of hundreds of millions 
of unique clusters. The reverse strands are cleaved and washed off followed by the blocking 
of fragment ends and hybridisation of the sequencing primer and at this stage the libraries 
are ready for sequencing. Hundreds of millions of clusters are sequenced simultaneously, 
base by base leading to the generation of results in a short period of time (up to a week). 
Four fluorescently labelled and reversibly terminated nucleotides are used to sequence the 
templates in parallel. The bases compete for template binding and this natural competition 
facilitates accuracy. After each round of synthesis, the clusters are excised by a laser 
emitting a colour that identifies the newly added base. The fluorescent label and blocking 
group are then removed for the addition of a new base (Ansorge, 2009). Deep sequencing 
generates millions of reads which are then analysed by technical bioinformatic techniques. 
The ability of deep sequencing to sequence clusters simultaneously allows for the 
sequencing of a mixture of different samples at the same time. The bar code within the 5’ 
linker will then be used to identify specific samples within the sequence results. As figure 3.5 
illustrates, analysis of the sequence results involves the identification of the 5’ and 3’ linkers 
in order to determine the insert. These linkers are also useful in the reverse transcription 
and PCR stages of the assay as primers are designed from their known sequences.  
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Fig 3.6: Outline of the Illumina Genome Analyser workflow (Ansorge, 2009). The three 
steps involved are the library preparation (I), Cluster generation (II) and sequencing-by-
synthesis reactions (III). 
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3.2 CRAC Optimisation 
Initial experiments were carried out to optimise and establish the best conditions for 
efficient transfection of the HEK-Flp293 cells with the plasmid expressing viral miRNAs of 
interest and induction of the tagged Ago-2 protein. HEK-Flp293 is a cell that stably expresses 
the doxycycline inducible tagged Ago-2 and was created using the Flip in™ expression vector 
system. The efficiency of IgG antibody conjugation to the Dynabeads was checked against 
commercially conjugated agarose beads. 
3.2.1 Transfection 
Previous experiments in the Grey laboratory have demonstrated that transfection of 
HEK293 cells with Fugene HD results in efficient introduction of plasmid DNA with little or 
no cytotoxic effects on the cells. To establish the best transfection conditions, a six well 
plate was seeded with 1 x 106 cells per well and transfected with varying ratios of GFP 
plasmid DNA and Fugene as detailed in the table in figure 3.7. 
 
Fig 3.7: Transfection optimisation results. Fluorescent Microscopy images demonstrate 
different transfection levels from using varying Fugene and plasmid DNA amounts as 
detailed in the table below image. 
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The fluorescent microscopy pictures in fig 3.7 indicate the different levels of transfection 
from using different amounts of Fugene and plasmid DNA. The Fugene:DNA ratio 
manufacturers’ recommended to use per well of a six well plate are 3µl:1µg. Few green cells 
were observed from transfecting the cells with the recommended amounts. Our results 
however show that optimal levels of transfection were achieved with higher Fugune:DNA 
ratios. For reagent and cost efficiency, a 5:1.5 (Fugene:DNA) ratio was chosen for future 
experiments.  
3.2.2 Induction 
The Ago-2 protein in HEK 293flp cells is doxycycline inducible. Using different doxycycline 
concentrations, ranging from 0µg/ml to 500µg/ml, the best concentration for efficient 
induction was determined. Following induction of a six well plate, the levels of expression of 
the Ago-2 protein was confirmed by western blotting using an antibody that recognises the 
Protein A tag. 
 
Fig 3.8: Induction check. Western blot results for checking levels of induction using different 
doxycycline concentrations. 
 
Western blot results were indicative of successful induction of the Ago-2 protein with an 
exception of when 0µg/ml of doxycycline was used. There was no difference in the resulting 
expression from the rest of the varying doxycycline amounts used. The cell line was 
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3.2.3 Conjugation of IgG to Dynabeads 
Previous studies by the Tollervey laboratory have demonstrated that IgG conjugated 
Dynabeads produce the best results in the context of CRAC assays with good efficiency of 
pull down with low levels of non-specific binding. An initial procedure is required to 
conjugate purified IgG antibody to magnetic Dynabeads (see materials and methods). The 
IgG antibodies were conjugated to Dynabeads and checked against commercially produced 
agarose beads for successful conjugation and pull down efficiency. The effect of lysate 
concentration on the IPs was also investigated to determine an optimum starting lysate 
concentration for IP. For a full scale CRAC assay, four 15cm dishes are seeded with 3 x 107 
HEK-293 cells, transfected and harvested into 10ml of lysate. 30mg of conjugated 
Dynabeads are used for IP. For this optimisation procedure, a small scale IP experiment 
where 300µg of conjugated Dynabeads were used for an IP from 100µl, lysate was set up. 
Following IP, complexes were eluted from the Dynabeads using a protein loading dye. These 
served as samples for analysis using western blotting. Three different lysate concentrations 
were checked, as obtained from harvesting (100% concentrated), 1 in 4 dilution of the 
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Fig 3.9: Dynabeads conjugation check and effect of lysate concentration in IP 
effectiveness. Panel A shows IP results from 100 lysate, B from 25% lysate and C from 10% 
lysate.  IP = immunoprecipitation sample and FT = flow through sample. 
 
The western blot results detected the presence of the Ago-2 protein in the lysates and IP 
samples.  Although the results are not quantitative, it is clear that the conjugated beads 
resulted in a relatively effective IP compared to agarose beads. The same western blot 
results also indicate that the extent of complex isolation has a positive correlation with 
lysate concentration and therefore the best results were from the IPs conducted from 
higher lysate concentration (100 %).  
3.2.4 Discussion  
Following these optimisation steps, it was decided that transfection levels obtained from 
using the Fugene:DNA ratio of 5:1.5, equating to 120µl of Fugene and 30µg of plasmid DNA 
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conducted using 500µg/ml of doxycycline. IPs were also to performed from 100% lysate 
using IgG conjugated Dynabeads for the first IP.  
3.3 CRAC 
Having established the conditions summarised in section 3.2.4, we followed the protocol as 
detailed in the appendix section 5.2.3. In this project, using a plasmid encoding for the miR-
US25 cluster (pCMV US25) we aim to study the HCMV US25 miRNAs. The specific miRNAs 
expressed by this plasmid (figure 3.10) are miR-US25-1-5p, miR-US25-2-3p and miR-US25-2-
5p. Several transcripts have been identified to be targeted by the miR-US25-1, therefore 
using this plasmid, we can refer back and confirm these findings as well as potentially 
identify new target transcripts for any of the three miRNAs.  
 
Fig 3.10: miR-US25-1 and -2 expressing plasmid with a CMV promoter upstream of the 
miRNA genes. 
pCMV US25 was transfected into HEK-293 cells and cellular lysates generated as detailed in 
the section 2.5 to obtain samples for CRAC analysis. A parental plasmid with GFP was used 
for the generation of a negative control sample. Three other HCMV miRNAs, miR-US5-2, 
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In the initial CRAC attempt, a 3,000 Ci/mmol γ-P32 radioactive isotope was used for the 
radioactive labelling, but unfortunately no signal was generated on the film after an 
overnight exposure. A higher activity γ-P32 isotope of 6,000 Ci/mmol was then used for the 
proceeding assays.  
3.3.1 CRAC Attempt 2 
 
Fig 3.11 (A) developed film from membrane exposure and (B) the proceeding PCR products 
gel results. Red boxes represent excised sections of the membrane and gel. 
After gel purification, the complexes were transferred onto a membrane which was exposed 
to film overnight. The results from the developed film are shown in fig 3.11(A). Clearly, the 
results show a difference in the amounts of complexes present from the two IPs with the 
pSiren GFP sample showing the presence of more signal compared to pCMV25 sample. This 
could be a result of loss of material during precipitation stage of the protocol that leads to 
the generation of a highly unstable pellet. The presence of other species of a higher 
molecular weight that leads to the smear above the band of desired size is also difficult to 
explain. A likely possibility could be less effective stringent washes during the IP and 
purification stages.  
Ago-2 has a molecular weight of approximately 100 kDa and a band representing this was 
identified (figure 3.11). Regions of membrane indicated by the red boxes were excised and 
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is PCR amplified and the products separated by gel electrophoresis using a 3% metaphor 
agarose gel and the results are illustrated in Figure 3.11(B). PCR gel purification results show 
a characteristic prominent band at approximately 150 base pairs with a smear above the 
band. It is difficult to explain what the contents of the smear are, but it is clear from the 
sizes of the contents, approximately 300 to 600 bp, that they are not the expected products. 
The prominent band however is within the expected products’ size range, therefore the 
section indicated by the red box was excised from the gel and products were extracted for 
further analysis. 
To determine the quality of these results, cDNA was TA cloned using the One Shot TOP10 
Invitrogen Topo™ plasmid kit. Following transformation of bacteria, individual clones were 
picked, mini prepped and sequenced. Twelve samples derived from cells transfected with 
pCMV miR-US25 were sequenced and the results are summarised in table 3.1. At this stage, 
results would confirm successful ligation of the 3’ and 5’ linkers. Inserts of 20 to 50 bases 
would be expected, demonstrating successful IPs. However, due to the nature of the small 
scale sequencing, a full picture of the contents of the cDNA library is limited compared to 
the results deep sequencing would generate. Therefore, the presence of longer sequences 
representing miRNA-RNA hybrids formed from the intra-molecular ligation step would be 
difficult to detect from small sequencing results.  Analysis of the sequencing results involved 
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Fig3.12: Demonstration of a small scale sequencing result from a TOPO cloned cDNA 
sample. 5’ linker is shown in red and the barcode (within the 5’ linker) in blue. 3’ linker is 
shown in green. The sequence between the linkers is identified as the insert and using the 
NCBI BLAST tool can be analysed and identified. 
 
Table 3.1: Small sequencing results. 
CRAC 2     
Sample Insert Sequence Seq length % match BLAST Result 
CMV25 (1) TGGAGAGAAAGGCGGTTCCTG 21 95% (20/21) MIR185-5p 
CMV25 (2) ACCCGCGATCTTCGGTTTACG 21 67% (14/21) Homo sapiens solute carrier 
family 9, member 11 
CMV25 (3) T 1 N/A N/A 
CMV25 (4) GTCCGAGCCACTGAGCGGTT 20 75% (15/20) inositol 1,4,5-trisphosphate 
receptor, type 2 
CMV25 (5) ACGATCCGAGCCACTGAGCGGTT 23 65% (15/23) inositol 1,4,5-trisphosphate 
receptor, type 3 
CMV25 (7) GGTCCGAGCCACTGAGCGGTT 21 71% (15/21) inositol 1,4,5-trisphosphate 
receptor, type 4 
CMV25 (8) AGACCCAGTAGCCAGATGTAGCT 23 100% (23/23) MIR222-3p 
CMV25 (9) G 1 N/A N/A 
CMV25 (10) TTCCCCATGGGGAGCT 16 N/A No significant homology. 
CMV25 (11) No 3' Linker detected N/A N/A N/A 
CMV25 (12) AGACCCAGTAGCCAGATGTAGCT 25 100% (25/25) MIR222-3p 
 
Analysis of the sequencing results revealed the presence of an insert between the linkers. 
This suggests the RISC-IPs were successful also supported by the BLAST results, which 
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indicated that three of the sequenced samples were miRNAs - miR-185-5p and miR-222-3p. 
The detection of transcripts, inositol 1,4,5-triphosphate receptor and the homo sapiens 
solute carrier, from the BLAST results was also encouraging. As expected, longer insert 
sequences were not detected as 23 bases was the longest sequence achieved. The shorter 
sequences obtained from this assay could however be reflective of the extent of RNase IT 
enzyme digestion. Two sequences had a single nucleotide insert and a 3’ linker was not 
detected from one of the sequences. Therefore the effect of enzyme concentration was 
studied by using less concentrated RNase IT. For this assay, the stock RNase IT of 5,000 
units/ml was diluted by a factor of 10 (2µl + 18µl H2O) to give 0.5 units/µl and the final 
amount used for the reaction was 0.5 units (1µl of the diluted enzyme).  
3.3.2 CRAC Attempt 3 
The protocol was followed as in the appendix (section 5.2.3) but the amount of RNase IT for 
the on-bead digestion was altered.  The stock RNase IT was diluted by a factor of 20 and the 
final amount used for the reaction was 0.25 units.  
 
Fig 3.13: Developed film from membrane exposure (A), and the proceeding PCR gel results 
(B). 
The film was developed after an hour’s exposure of the membrane to the film. The band 
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the film, i.e. 1 hour. The membrane picture could also be representing a more successful 
stringency IP and purification during the procedure as there is less smearing. 
Bands representing the Ago-2 protein were excised as represented by the red boxes in (A) 
and RNAs extracted. The gel from PCR purified products of the samples is shown in (B). The 
bands were, however, faint without the characteristic smearing expected from the samples. 
Various reasons could explain the resulting faint bands including loss of material during 
some of the purification stages, particularly the sensitive precipitation stage. Gel loading 
was also challenging as samples proved to be volatile resulting in loss during loading of 
samples into wells. The products were nonetheless extracted from the marked area, cloned 
and DNA was purified from twelve individual clones for small scale sequencing.   
Table 3.2: Small sequencing results. 
CRAC 3      
Sample Sequence Seq 
length 
% match BLAST Result 
CMV25 (1A) TGCAAATCTATGCAAAACTG 20 100% (20/20) microRNA 19a (MIR19A) 
CMV25 (3A) TACGGGCCACC 11 N/A Sequence too short 
CMV25 (4A) TCCCTGGTGGTCTAGTGGCTAGG 23 100% (23/23) hypothetical 
LOC100505703 
CMV25 (5A) TGTAAACATCCTACACTCTCAGCT 24 100% (24/24) microRNA 30C-1 
(MIR30C1), microRNA 
30C-2 (MIR30C2) 
CMV25 (6A) TAGCAGCACATCATGGTTTACA 22 100% (24/24) microRNA 15b (MIR15B) 
CMV25 (7A) TAGCTCAGCGGTT 13 N/A Sequence too short 
CMV25 (8A) GTCCGAACGCTAGGTTGGTTCT 22 21/22 (95%) HCMV miR-US25-1-3p 
CMV25 (9A) GAACGCTAGGTCGGTTCT 18 77% (14/18) NADH dehydrogenase 








TAGCAGCACGTAAATATTGGCG 22 100% (22/22) microRNA 16-1 (MIR16-1) 
 
Following analysis of the sequences, all twelve samples showed the presence of an insert. 
The minimum length of the inserts was eleven nucleotides, an improvement from the 
previous assay where the 3’ linker was not detected in one sample and two other samples 
had an insert of one nucleotide.  Six of the sequences showed 100% homology to the BLAST 
results. Of great interest was the presence of an HCMV miRNA, highlighted in red, as one of 
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the inserts. This is an encouraging result showing successful processing of the transfected 
pre-miRNA and incorporation into the RISC complex. The result further demonstrates that 
miRNAs transfected into the cells can be isolated together with cellular miRNAs.  
3.2.4 CRAC Attempt 4 
The CRAC assay protocol was followed with the amount of RNase IT further altered. The 
stock RNase IT was diluted by a factor of 160 and the final amount used for the reaction was 
3.125 x 10-2 units. In this assay expression constructs for 3 other viral miRNAs, pUS5-2, 
pUL22A-1 pUL112-1, were used. 
 
Fig 3.14: Developed film from membrane exposure and the proceeding PCR gel results. 
The film was developed after overnight membrane exposure. The membrane picture clearly 
shows the presence of products in different amounts. pUS5-2 had the most faint band. 
pUL22A-1 and pUL112-1 also showed the presence of material of lager size than expected. 
Smaller products were also present in the pUL-22A-1 sample as shown by the smear below 
the main band.  
Bands representing the Ago-2 protein were excised as represented by the red boxes in (A) 
and RNAs extracted. The gel from PCR purified products of the samples is shown in (B). 
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product were obtained, suggesting amplification reached saturated levels. Gel loading 
problems with the samples “jumping-out” of the wells could have led to the resulting loss 
material from the pUL-112-1 sample.  Although the bands were prominent and well defined, 
the characteristic smearing expected from the samples was only present, to a small extent, 
in the pUL22A-1 sample. The products were nonetheless extracted, from the marked area, 
and the pUL22A-1 products were cloned and DNA was purified from twelve individual clones 
and sequenced.   
Table 3.3: Small scale sequencing results 
CRAC 4     
Sample Sequence Seq 
length 
% match BLAST Result 
UL22A - 1 (2) TAACTAGCCTTCCCGTGAG 19 100% (19/19) HCMV miR-UL22A-1 
UL22A - 1 (3) AACTAGCCTTCCCGTGAGA 19 100% (19/19) HCMV miR-UL22A-1 
UL22A - 1 (5) AGTGATTTGTTGTT 14 100% (14/14) protein (Cdc42/Rac) - 
activated kinase 2 (PAK2) 
UL22A - 1 (6) CCCTGGTGGTCTAGTGGCTAGGAT 24 100% (24/24) hypothetical LOC100505703 
UL22A - 1 (7) TAACTAGCCTTCCCGTGAGA 20 100% (20/20) HCMV miR-UL22A-1 
UL22A - 1 (8) CAGAATGCTAGTTTGTAG 18 N/A No significant homology 
UL22A - 1 (9) AACTAGCCCCGTGAGA 16 100% (16/16) Toll-interleukin 1 receptor 
(TIR) 
UL22A - 1 (10) TAAAGTGCTGACAGTGCAGA 20 100% (20/20) microRNA 106b (MR106B) 
UL22A - 1 (11) ACTGCTGAGCTAGCACTTCCCGA 23 100% (23/23) microRNA 93 (MIR(93) 
UL22A - 1 (12) ATGCTAGTTTGTAG 14 N/A No significant homology 
 
Sequencing results indicate some change in the length of the inserts, with the shortest 
inserts having 14 nucleotides compared to results from the previous assay, which had the 
shortest insert of 11 nucleotides. 25% of the sequenced samples returned the presence of 
the HCMV miR-UL22A-1 miRNA. Sequences that returned results on BLAST search tool had a 
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3.2.5 CRAC Attempt 5 
This assay aimed at investigating the reaction time during on bead digestion. The CRAC 
assay protocol was followed, as well as altering the amount of RNase IT, the reaction was 
also altered. The stock RNase IT was diluted by a factor of 80 and the final amount used for 
the reaction was 6.25 x 10-2 units. To investigate the effect of reaction time, RNase IT on-
bead digestion was carried out for 3 mins as opposed to the 5 mins on the protocol. 
 
Fig 3.15: Developed film from membrane exposure (A) and the proceeding PCR gel results 
(B). 
The membrane was exposed to the film for an hour and the results from the developed film 
are shown in (A). The resulting PCR gel however indicted the presence of the products in 
small amounts. They were however cloned and 12 individual clones picked for each sample, 
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Table 3.4: Small sequencing results. 
CRAC 5     
Sample Sequence Seq 
length 
% match BLAST Result 
CMV25 (1B) TAACTGCTCAGTGGCTCGGACCG 23 21/23 HCMV miR-US25-1-5p 
CMV25 (2B) TAAAACTCA 9 N/A Sequence too short 
CMV25 (3B) No Insert 0 N/A N/A 
CMV25 (4B) TATTGCACTTGTCCTGGCCTG 21 95% (20/21) microRNAs 92a-1, 92a-2 & 
17-92 (MIR92a-1, 92a-2, 
MIR17-92)  
CMV25 (5B) No Insert 0 N/A N/A 
CMV25 (6B) No Insert 0 N/A N/A 
CMV25 (7B) AACCGCTCAGTGGCTGGAC 19 15/19 (79%) hypothetical LOC100507663 
CMV25 (8B) AATTCCCCGACGGGTT 16 13/16 (91%) Homo sapiens 
phosphohistidine 
phosphatase 1 
CMV25 (9B) TCGGGTATGAGCC 13 13/13 (100%) Homo sapiens CDC42 






36 N/A No significant homology 
CMV25 
(11B) 
TAAAACTCAA 10 N/A Sequence too short 
CMV25 
(12B) 
No Insert 0 N/A N/A 
     
pGFP N3 (1) 5' Linker Barcode not detected N/A N/A N/A 
pGFP N3 (3) GAATCCCAAAAGCAGCT 17 17/17 (100%) microRNA 191 (MIR191) 
pGFP N3 (4) ATACTGCCATGCTAGAGGACT 
GGAGAGGTG 
30 N/A No Significant homology 
pGFP N3 (6) GGGGAGTACGGTCGCAAGACTAA 
AACTCA 
29 N/A No Significant homology 
pGFP N3 (8) 5' Linker Barcode not detected N/A N/A N/A 
pGFP N3 (9) AAGGGAGAAATCAAGTAAATT 
ATCCAAGG 
29 29/29 (100%) Chromosome 12 genomic 




No Insert N/A N/A N/A 
pGFP N3 
(11) 




GAcTAAAACTCA 12 N/A Sequence too short 
 
Sequencing results from this assay (table 3.4) indicates the presence of inserts with a 
broader range, from 0 to 36 nucleotides in length. Four different sequences of lengths 29, 
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29, 30 and 36 were encouraging. However analysis of the sequences has failed to determine 
what they are composed of. As with previous assays, a HCMV miRNA was detected as well 
as cellular miRNAs and transcripts. The same conditions were maintained for the 
subsequent assay. 
3.2.6 CRAC Attempt 6 
Using duplicate samples, 2 lysate samples for pCMV25 and 2 for pGFP transfected HEK-293 
cell lines, the protocol was followed with the conditions in CRAC attempt 5 maintained, i.e. 
6.25 x 10-2 units of RNase IT and a reaction time of 3 mins. 
 
Fig 3.16: Developed film from membrane exposure and the proceeding PCR gel results. 
The membrane was exposed to the film for an hour and the results from the developed film 
are shown in (A). Products were present on the membrane in different quantities. The gel 
picture (B) indicates the presence of products in the samples from purified PCR products. A 
prominent band was present at approximately 150 bp, as well as the characteristic smearing 
that is a result of the presence of products of different lengths were clear on the gel results. 
Sections marked with red boxes were excised from the gel and products were extracted. 
These were TOPO cloned and cDNA from six individual colonies from each sample were 
picked, cultured and mini prep purified for sequencing. The analysed sequencing results are 
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Table 3.5 Small sequencing results. 
CRAC 6     
Sample Sequence Seq 
length 
%Match Blast Result 
CMV25 (1C) CAAAGTGCTCACAGTGCAGGTAG 23 22/23 (96%)  microRNA 20b (MIR20B), 
microRNA 17 (MIR17), miR-17-
92 cluster host gene 
CMV25 (2C) 5' Linker Barcode not detected    
CMV25 (3C) CAAAGTGCtcacaGTGCAGGTAG 23 22/23 (96%)  microRNA 20b (MIR20B), 
microRNA 17 (MIR17), miR-17-
92 cluster host gene 
CMV25 (4C) TAGCAGCACGTAAATTGG 18 15/18 (83%) microRNA 16-1 (MIR16-1), 
microRNA 16-2 (MIR16-2) 
CMV25  (5C) TAGATCCGAATTTGT 15 15/15 
(100%) 
microRNA 10a (MIR10A) 
CMV25 (6C) TATTGCACTtgtCCCGGCctg 21 21/21 
(100%) 
microRNA 92a-2 (MIR92A2), 
microRNA 92a-1 (MIR92A1), 
miR-17-92 cluster host gene 
     
CMV25 (1D) AACCGCTCAgTGGCTTGGACC 21 15/21 (76%) inositol 1,4,5-trisphosphate 
receptor, type 2 (ITPR2) 
CMV25 (2D) AACCGCTcagTGGCTCGGAC 20 15/20 (80%) inositol 1,4,5-trisphosphate 
receptor, type 2 (ITPR2) 
CMV25 (3D) AACCGCTCAGTGGCTCGGACC 21 15/21 (76%) inositol 1,4,5-trisphosphate 
receptor, type 2 (ITPR2) 
CMV25 (4D) TAAGGTGCATCTAGTGCAG 19 19/19 
(100%) 
microRNA 18b (MIR18B), 
microRNA 18a (MIR18A), miR-
17-92 cluster host gene 
CMV25 (5D) AACCGCTCAGTGGCTCGGA 19 15/19 (78%) inositol 1,4,5-trisphosphate 
receptor, type 2 (ITPR2) 
CMV25 (6D) AACCGCTCAGTGGCTCGGAC 20 15/20 (80%) inositol 1,4,5-trisphosphate 
receptor, type 2 (ITPR2) 
     
pGFP C1 (1) ACAGGgtAGAACCACGGA 18 100% 
(18/18) 
microRNA 140 (MIR140) 
pGFP C1 (2) No Insert detected 0 N/A N/A 
pGFP C1 (3) No sequence result N/A N/A N/A 
pGFP C1 (4) TTtgGCAATGGTAGAACTCACAct 24 100% 
(24/24) 
microRNA 182 (MIR182) 
pGFP C1 (5) AGtGGTTAG 9 N/A Sequence too short 
pGFP C1 (6) TACCCTGTAGATCCGAATTGT 21 100% 
(21/21) 
microRNA 10a (MIR10a) 
     
pGFP N3 
(1A) 
GTCCGAACGCTAGGTCGGTTC 21 N/A No sequence homology 
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pGFP N3 
(2A) 
ACGCGGGAGaCCGGGGTT 18  Homo sapiens nuclear receptor 
subfamily 0, group B, member 1                                                                                                             
Homo sapiens 
oligonucleotide/oligosaccharide-
binding fold containing 1 
(OBFC1), mRNA Homo sapiens 
HtrA serine peptidase 3 
(HTRA3),                                                                                                                                    
mRNA Homo sapiens PDZ 
domain containing 1 
pseudogene 1 (PDZK1P1) 
pGFP N3 
(3A) 





AGtgGCTCGGACCG 14 13/14 (93%) Homo sapiens DC-STAMP 
domain containing 2 (DCST2) 
pGFP N3 
(5A) 
GGGgAgCCTC 10 N/A Sequence too short 
pGFP N3 
(6A) 
No Insert detected N/A N/A N/A 
 
Other than four samples, where either no insert or linker were detected or sequencing 
failed, the insert sequence lengths were consistent with results from the previous CRAC 
assay attempt. A BLAST search returned results with both miRNAs and transcripts present.  
The averages of the insert sequence lengths from all CRAC attempts were calculated and are 
detailed in table 3.6. The sequence lengths from each assay were also plotted (figure 3.17) 
for a clear visualisation of their ranges. 
 Table 3.6: Summary of CRAC Assay results and conditions used. 
CRAC Attempt Conditions used Average Sequence 
Length 
RNase Dilution factor Reaction time (mins) 
1 10 5 17.2 
2 20 5 19.4 
3 160 5 18.8 
4 80 3 20.14 
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The averages of the sequence lengths indicate that a reduction in the reaction would 
potentially increase the sequence lengths. A more effective and comparative way of 
studying these results is illustrated in figure 3.17. 
 
Figure 3.17: CRAC Assay sequence lengths. 
The gel and sequencing results collectively show that the CRAC assays worked to some 
extent. The results are encouraging as longer sequences specifically from CRAC attempt 4 
were achieved. Also, the detection of transcripts, miRNAs as well as HCMV miRNAs initially 
transfected into the cells is indicative of the functionality of the assays.  The four samples 
generated in CRAC attempt 6 were submitted for deep sequencing analysis. Preliminary 
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CHAPTER 4: Conclusions 
The identification of HCMV miRNA targets will provide greater understanding and 
knowledge of the biology of herpes viruses. Previous studies have demonstrated that herpes 
virus miRNAs’ targets both host and viral transcripts. Identified targets include transcripts 
involved in apoptosis, innate immunity, cell survival and proliferation as well as mimicking 
cellular miRNAs with resulting effects favouring the biological life cycle of the viruses. The 
viral MIE trans-activating region has been shown to be targeted by the viral miRNAs, for 
example, targeting of the HCMV IE72 gene by the miR-UL112-1. With the majority of the 
miRNA targets not identified, questions remain as to what their targets are, why those 
transcripts would be targeted and at what stage of the viral biological life cycle these 
miRNAs control target genes? The CRAC technique will improve on previous techniques and 
offer an extensive and valuable platform for these studies. The CRAC assay improves the 
RISC-IP assays, specifically by reducing background noise by the provision of a 2 step IP and 
the high stringency conditions in which the assay can be conducted due to UV crosslinking. 
Also, target transcripts can be identified together with the targeting miRNA due to the intra-
molecular ligation reaction. miRNA targets on both viral and cellular genomes can also be 
investigated simultaneously with the use of deep sequencing which offers an in-depth 
analysis on a large scale as opposed to microarray which is dependent on the pre-designed 
probes. 
The extent of success of the CRAC assays from these studies will be revealed by the deep 
sequencing results that are currently under analysis. However, as illustrated in this report’s 
detailed results, we investigated and established the best conditions for transfection of 
miRNA expression plasmids and induction of tagged Argonaute for the production of quality 
CRAC lysate samples. We also demonstrated that antibody conjugation of Dynabeads was 
efficient and capable of pulling down target complexes, a fact supported by the small 
sequencing result analysis. 
To some extent, the small sequencing results strongly indicate the success of the CRAC assay 
protocol on the whole. The incorporation of the 5’ and 3’ linkers was confirmed by the small 
scale sequencing. The presence of cellular transcripts and miRNAs as well as transfected 
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plasmid encoded miRNAs in some of the assay results was immensely encouraging. It would 
have been interesting if we had managed to establish what exactly the longer inserts of 30 
and 36 nucleotides from CRAC attempt 5 were composed of, or achieved longer sequences 
with a miRNA and target transcript together indicating that the intra-molecular ligation was 
achieved. Deep sequencing results will elucidate the success of this step as it was 
anticipated that this would be a rare event and small sequencing results would most likely 
miss the resulting miRNA/mRNA hybrid reads. 
We investigated the concentration of RNase IT and the digestion reaction time to establish 
how these factors would affect the insert lengths. Although, admittedly from the present 
results, RNase IT digestion effects arguably may not be the cause of smaller inserts obtained 
so far, deep sequencing results will be more informative.  It will be interesting to investigate 
the effect of 1:160 RNase IT dilution with the digestion reaction set up for 3 mins. Also, the 
recommended amounts of RNase IT, 0.5 units, can be used but altering the time of reaction 
to a longer time period and at a very low temperature, for example 4oC, profoundly slowing 
down the activity of the enzyme.  
In these studies, we have demonstrated the immense promise CRAC has in offering a cutting 
edge technology for studying viral miRNA targets. Although at a preliminary stage of 
analysis, initial results from deep sequencing indicate that over 100 million reads were 
captured between the four samples submitted. Of those, approximately 41 million reads 
contain 5’ and 3’ linker sequences with identifiable bar codes. Just less than 10 million reads 
correspond to miR-US25 miRNAs, indicating that the viral miRNAs were successfully 
incorporated into cellular RISC. Further analysis is on-going to determine insert lengths, 
composition of inserts and whether specific populations of sequence tags correspond to the 
samples transfected with the viral miRNAs. However, these results are encouraging and 
once this technique has been established it will be implemented in studying HCMV miRNAs 
 Future studies will be aiming to take advantage of the deep sequencing and its ability to 
provide high speed and throughput results. Therefore assays will be conducted on HCMV 
infected cells enabling the study of all HCMV encoded miRNA functions, through identifying 
their targets, as well as potentially discovering novel miRNAs. 
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5.2 Appendix 
5.2.1 Buffer Recipes 
5.2.1.1 Dynabeads-IgG conjugating Buffers 
 
0.1M Sodium Phosphate Buffer (NaPO4) – pH 7.4  
 
NaH2PO4 x H2O (MW 137.99)  2.62g 
Na2HPO4 x 2H2O (MW 177.99)  14.42g 
Dissolve in distilled water, adjust pH if necessary and adjust to 1 litre. This buffer is for pre-
washing beads, do not add any protein, sugar, etc.  
3M Ammonium Sulphate (stock solution)  
(NH4)2SO4 (MW 132.1)   39.6g 
Dissolve in 0.1M Sodium Phosphate Buffer (pH 7.4) and adjust to 100ml 
Phosphate Buffered Saline (PBS) -pH 7.4  
NaH2PO4 x H2O (MW 137.99)  0.26g 
Na2HPO4 x 2H2O (MW 177.99)  1.44g 
NaCl (MW 58.5)    8.78g 
Dissolve in 900mL distilled water, adjust pH if necessary and adjust to 1 litre.  
PBS + 0.5% Triton X-100  
Include 0.5% (w/v) Triton X-100 in 100 mL PBS solution  
100mM Glycine HCl pH 2.5  
10mM Tris pH 8.8  
10% Sodium Azide (NaN3)  
5.2.1.2 TBST 100ml 
10 x TBS   10ml 
Tween 20   0.05ml 
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5.2.1.3 SDS PAGE Gel Recipe (10%) 
Stacking Gel   Running Gel 
 
30% Acrylamide/0.8% Bis        3.3 ml        1ml  
1.5M Tris-HCL pH 8.7         2.5ml        833µl 
H2O           4.02ml        6.67ml 
10% SDS          100µl        10µl 
10% Ammonium Persulphate        100µl        50µl 
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5.2.1.4 CRAC Assay Buffers 
 In bold are the stock concentrations. 
 2-Mercaptoethanol (2ME) is to be added fresh just before using buffer. 
 
Lysis buffer   50ml 
 
50mM Tris pH 7.5   2.5ml  1M 
300 mM NaCl   3ml  5M 
1% NP-40   5ml 10% 
1mM EDTA   0.5ml 0.5M 
10% glycerol   10ml 50% 
5mM 2ME   25µl   100% 
 
Ni-EB 200        10ml 
 
50 mM Tris-HCl pH 7.8 0.5ml 1M 
50 mM NaCl   0.1ml 5M 
200mM Imidazole  2ml 1M 
0.1M NP-40   0.1ml 10% 
5mM ME   2.5µl  100% 
 
5 x PNK buffer     250ml 
 
250 mM Tris-HCl pH 7.5 62.5ml  1M 
50 mM MgCl2 (FW= 95.22) 1.19g 
2.5% NP-40    62.5ml  10% 
250mM NaCl   12.5ml  5M
   
 
1 x PNK buffer  
Contains 5mM 2ME during washes and 





Ni-WB I buffer                      50ml 
 
50 mM Tris-HCl pH 7.8 2.5ml 1M 
300 mM NaCl   3ml 5M 
10mM Imidazole  0,5ml 1M 
6M Guanidine-HCl  28.66g 
0.1M NP-40   0.5ml 10% 
5mM ME   25µl   100% 
 
Ni-WB II buffer  
Ni-WB I without Guanidine-HCl 
 
HS IgG-WB buffer              500ml 
 
50 mM Tris-HCl pH 7.5 25ml 1M 
0.8 M NaCl   80ml  5M 
10 mM MgCl2   10ml 0.5M 
0.5% NP-40    25ml 10% 
2.5% glycerol   25ml 
Water    335ml 
5 mM 2ME   250µl 100% 
 
LS IgG-WB buffer                 500ml 
 
50 mM Tris-HCl pH 7.5 25ml 1M 
0.3 M NaCl   30ml  5M 
5 mM MgCl2    5ml 0.5M 
0.5% NP-40    25ml 10% 
2.5% glycerol   25ml 
Water    390ml 
5 mM 2ME   250µl 100% 
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5.2.2 Protocol for Conjugation of Dynabeads with Rabbit IgG 
Adapted from Rout Lab Protocol, Last Modified by Karen Wei 3/26/07. 
Coupling of Dynabeads with Rabbit IgG in order to produce magnetic beads which are 
capable of pulling out various Protein A tagged complexes.  
Note: We are using rabbit IgG -100mg -from Sigma – catalogue number 15006 Dynabeads 
are from Invitrogen -Dynabeads M270 Epoxy Day ay One – Preparing the Beads and 
Conjugation 
 1) Resuspend entire vial of Dynabeads (2 x 1010 beads) in 16ml of 0.1M NaPO4 buffer (pH 
7.4). 
2) Vortex bottle 30 seconds.  
3) Divide bead suspension into four 15ml Falcon tubes (4mL of suspension in each tube).  
4) Wash any remaining beads in the glass vial with an additional 2ml of 0.1M NaPO4 buffer. 
Divide equally amongst the four Falcon tubes.  
5) Shake bead suspension slowly for 10 minutes on a Nutator or rocking platform.  
6) While bead suspension is on Nutator prepare the AB mix.  
a. FIRST: Re-suspend the entire bottle of Rabbit IgG (100mg) in 7ml double distilled H2O – 
this will result in a concentration ~14mg/ml. Aliquot into 1mL fractions and store any 
unused IgG at -20°C.  
b. Spin down 3525µl, of Rabbit IgG, in a table top centrifuge, for 10 mins, at 14 000 rpm, at    
4°C. Save supernatant and discard pellet.  
c. Prepare AB mix by adding the solutions to a 50mL falcon tube, in the order listed.  
i) 3525µl of IgG (which was previously spun down) If IgG concentration needs to be altered 
please see end of protocol for instructions on determining appropriate amounts of Sodium 
Phosphate and Ammonium Sulphate  
ii) 9.850mL 0.1M NaPO4 buffer.  
iii) 6.650ml 3M Ammonium sulphate. Add slowly shaking the tube a bit.  
iv) Filter solution using a 0.22μm Millex GP filter  
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 7) Place the Falcon tubes with the bead suspension onto a magnetic holder and wait until 
all beads are attached to the magnet (Dynal MPC-6 Magnetic Particle Concentrator Prod. 
No.120.02). Bead solution will appear clear. Aspirate the buffer off (be careful not to 
aspirate off the beads too).  
8) Wash again with 4mL 0.1M NaPO4 -incubation for 10 minutes is not necessary. Vortex 15 
secs. Put on the Magnet -aspirate off the buffer.  
9) Add 5ml of AB mix to each tube vortex to completely combine the AB mix and the beads.  
10) Wrap tops of Falcon tubes with parafilm and place on rotating wheel at 300C overnight 
(incubation must last at least 18 hours but no more than 24 hours).  
Day Two -Washing the Dynabeads after Conjugation  
Do all washes as described in the 15ml Falcon tubes. You can aspirate the supernatant by 
using a Vacuum Aspirator.  
1) Wash once with 3mL of 100mM Glycine HCL pH2.5. Put it on and take it off as fast as 
possible.  
2)  Wash once with 3ml of 10mM Tris pH 8.8.  
3) Wash once with 3mL of 100mM Triethylamine. (Make fresh 100mM Triethylamine by 
adding 168µl stock to 11.156ml of DDH20). Put it on and take it off as fast as possible. 
4) Wash the coated beads with 1x PBS for 5 minutes – washes should be done on a 
rocker/nutator – repeat x4. 
5) Wash once with PBS + 0.5% Triton X-100 for 5 minutes.  
6) Wash again with PBS +0.5% Triton X-100 for 15 minutes on rocker/nutator.  
7) Finally, resuspend all beads in a total of 2ml of 1x PBS + 0.02% Sodium azide.  
8) Store the coated beads at 40C.  
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Day 1 (full day ~9hrs) 
 
First  IP - IgG – Dynabeads  
Argonaute-2 protein, part of the RISC complex, is binds to the IgG conjugated dynabeads via 
the protein A. 
 
Beads freshly coated – 14301 (invitrogen), 60mg (amount for 3 samples, 20mg each), stored 
at 4C in PBS + 0.02 % sodium azide 
 
 LOADING - always keep beads on ice! 
 
IgG Dynabeads solution (washed directly before use 3 x with 5ml PBS, beads vol. about 70ul) 
– this is to get rid of IgG that is in solution.   Beads mix then divided into 3 (3 falcon tubes) 
and extract added. 
 
Incubation for 45 mins, temp = 4oC, rotation  
 
Flow through (SAVE FOR WESTERN BLOT) 30ul + 30ul 2 x SB  5’ 95C (Western to show no 
protein as the RISC complex is meant to have been bound to the Dynabeads.) 
 
 WASHES:  
 
1 x LS-IgG WB buffer (vol. = 5ml)  fast 
2 x HS-IgG WB buffer (vol. = 5ml) 5 mins cold room - rocker 
1 x LS-IgG WB buffer (vol. = 5ml)  fast 
LS for Low Salt and HS for High Salt and these buffers get rid of non-specific binding!!! 
 
Resuspend in 1ml PNK5 buffer and transfer in eppendorf, put on the small magnet 
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RNAse digestion  
This step aims to digest the hanging target mRNA on both sides of the miRNA bound part. 
 
 Beads re-suspended in pre-warmed/room temp 500l PNK5 buffer + 0.5 unit 
RNAseA+T1 mix (1ul of 1:20 dilution in H2O of RNase-IT cocktail kept at 4
oC; agilent 
400720: Stock has 5000 units/ml and this has been diluted in water at a ratio of 1:10 
and use 1l of that to get the 0.5 units required.) 
 
Time = 5 mins, temp = 20oC, water bath (tap once during 5 min so beads don’t settle) or use 
thermoshaker at 20oC and 500 rpm. 
Transfer onto ice for 1’ (no longer) to slow down the reaction, discard RNase mix and 
proceed immediately to the next step. 
(should not let RNase work longer and the guanidine of the elution buffer will inactivate it) 
 
 ELUTION  
3 x 250l Ni-WB I buffer 10 mins at 20oC (on rotator or wheel, or thermoshaker), pool the 
fractions together (750L final volume per sample) 
 
Second IP - Ni-NTA  
Binding of the His tag to the Nickel beads for the second part of the RISC IP. His-tag: an 
amino acid motif made up of 6 histidines. 
 
Equilibrate the Ni-NTA resin with Ni-WB I   (take 80 l slurry per sample, wash 2X with Ni-
WB I) spin 1000 g ~ 20 sec, remove supernatant, add new buffer, etc). ** May help to use a 
lamp to see beads when removing liquid.  
 
Ni-NTA resin is from Qiagen “Ni-NTA superflow, 25 ml”  
 
 LOADING 
Add 50ul Ni-NTA slurry (about 50%) to eluate from the IgG resin  
 
Incubated for 2 hours 4oC, rotation 
 
 WASH: 
2 x Ni-WB I buffer, 0.75 ml rocking at 4oC  for 10 mins. 
 
Beads transferred to the Pierce columns (Spin column snap cap # 69725) 
2 x Ni-WB II buffer, 0.75 ml  
3 x PNK5 buffer 0.75 ml  
(When using the Ni-WB I buffer before an enzymatic reaction think of washing it away well 
to not inhibit the enzyme, try to deposit the volume on the bottom of the column and not 
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Phosphorylation (on column) 
(Put the little cap at the bottom of the column) 










(Close the lid of the column)  Time= 2h 30 mins, temp = 20 oC 
 
“On-bead intra-molecular ligation” (on column) 
































 1x 3x 
ATP (stock 100mM, final 1mM)   0.8l 2.4ul 
RNAsin (20u/µl stock) 2l 6ul 
T4 PNK (5u/µl stock) 4l 12ul 
5 x PNK10 buffer  16l 48ul 
water  57.2l 171.6ul 
TOT  240 ul  
 1x 3x 
ATP (stock 100mM, final 1mM)   0.8µl 2.4µl 
RNAsin (20u/ul stock) 2µl 6µl 
T4 RNA ligase I 4µl 12µl 
5 x PNK10 buffer  16µl 48µl 
water  57.2µl 171.6µl 
TOT  240 µl  
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Day 2 (short day ~2hrs) 
(Open the lid of the column and then remove the cap) 
 
 WASH: 
1 x Ni-WB I buffer, 0.4 ml  
1 x Ni-WB II buffer, 0.75 ml 
3 x PNK buffer, 0.75 ml 
(Ni-WB1 buffer contains guanidine which stops the ligation reaction . The imidazole present 
at low conc. gets rid of the non-specific binding to the Ni-beads.) The following washes will 
be to remove any residual NI-WB 1.) 
 
Dephosphorylation (on column) (of the 3’ end which will allow the ligation of the 3’ linker). 
(Close the lid of the column to eliminate the maximum of the wash volume, put back the 
cap at the bottom and open the lid again) 








Time = 45 mins, temp. = 20oC  
 
 (Open the lid of the column and then remove the cap) 
 
 WASH: 
1 x Ni-WB I buffer, 0.4 ml 
1 x Ni-WB II buffer, 0.75 ml 


















 1x 3x 
TSAP 8µl 24µl 
RNAsin (20u/µl stock) 2µl 6µl 
5 x PNK10 buffer  16µl 48µl 
Water  54µl 162µl 
TOT 80µl 240µl  
 
75 
Stephen M Chiweshe (s1161257) CRAC 
3’ linker ligation (on column) 
 (This a linker with a known sequence which will allow amplification and sequencing) 
(Close the lid of the column to eliminate the maximum of the wash volume, put back the 
cap at the bottom and open the lid again) 
 












Time = 10-24 hrs, temp = 16oC  





            
                                                            
 1x 3x 
3’ linker (miRCat-33, 10M)  
Kept at -80! 
8µl 24µl 
T4 RNA Ligase II, truncated K227Q 
(M0351) 
4µl 12µl 
RNAsin (20u/ul stock) 2µl 6µl 
PEG 8000 (stock 25%, final 10%) 32µl 96µl 
5 x PNK10 buffer 16µl 48µl 
Water 18µl 54µl 
 80µl 240µl  
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Day 3 (very long day ~ 12hr +) 
 




1 x Ni-WB I buffer, 0.4 ml 
1 x Ni-WB II buffer, 0.75 ml 
3 x PNK buffer, 0.75 ml 
 
(Close the lid of the column to eliminate the maximum of the wash volume, put back the 
cap at the bottom and open the lid again) 
 
Radioactive labelling of RNA (on column)  
Addition of a radioactive phosphate at the 5’ end of the miRNA/mRNAs 









Time= 40 mins, temp = 37oC 
 
!!Open the lid of the column and only then remove the cap!! 
!! First and second wash in the radioactive liquid waste!! 
 
 WASH: 
1 x Ni-WB I buffer, 0.4 ml  
1 x Ni-WB II buffer, 0.75 ml 
3 x PNK buffer, 0.75 ml 
(close the lid of the column to eliminate the maximum of the wash volume, put back the cap 
at the bottom and open the lid again) 
 
ELUTION  
Elution buffer which contains imidazole at high concentration disrupts the Histag-Ni 
interaction by competitive binding. 
 
Beads resuspended in the elution buffer (Ni-EB 200mM Imidazole), 2 x 200µl, 1x 600µl, 5 






 1x 3x 
32P-ATP 3µl 9µl 
RNAsin (20units/l stock) 2µl 6µl 
T4 PNK (5l stock) 4µl 12µl 
5 x PNK buffer 16µl 48µl 
Water 55µl 165µl 
 80µl 240 µl 
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TCA precipitation 
Precipitation of proteins and brings the volume down to enable loading onto the gel. 
1ml of eluate + 2g BSA + 200µl 100% TCA 30’ on ice. 
Centrifuged full speed for 20 mins, 4 oC 
 
!! TCA supernatant in the TCA radioactive waste!!  
 
Washed 2x with 1 ml cold acetone (-20 oC), vortexed in between, 10 mins spin 
 
!! Acetone washes in the TCA radioactive waste!! 
 
Pellet dried at 37 oC, re-suspended in 10µl water, then 10µl 2 x SB (NuPage) added, 10 mins 
at 65 oC. 
(Do not over-dry the pellet after TCA precipitation otherwise it becomes very difficult to re-
suspend; do not pipette, do not touch the pellet with the tip) 
 
 
Gel- using precast: 
 
NuPage 4-12% gel (10 well; product NP0335BOX, Invitrogen) 
NuPage MOPS SDS Running buffer, 20X (NP000102) 
NuPage Transfer Buffer (NP00061) 
 
Load samples along pre-stained ladder, leave space in between samples!!!! 
 Run ~ 40 min to 1 hour at 150 V. 
A band of approximately 100kd of Ago 2 + Histag +mRNA/miRNA-3’ linker is expected. 
Transfer to nitrocellulose in transfer buffer (on ice) for 2 hours at 100 V. 
 
Expose to film with a fluorescent ruler, 30’ and 2h if not strong enough.  
 
Note: At this point it is possible to store the membrane at -80 overnight and continue on 
Day 4 although this isn’t ideal 
 
Put the film over the membrane and with a needle pierce film and membrane in 
correspondence to the band to cut. Then use the holes on the membrane as a reference to 
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Proteinase K treatment  
Proteinase K digests the proteins which will be bound to the membrane and therefore 
releases the miRNA.  
 Bands cut out of the membrane and incubated for 2 hrs, at 55oC in the 400µl 
proteinase K mix. 
 
Proteinase K mix: 
    50ml 
50mM Tris-HCl  2.5 ml 1M 
50mM NaCl      0.5ml 5M 
10mM imidazole  0.5ml 1M 
0.1% NP-40   0.5ml 1M 
1% SDS   5ml 10% 
5mM EDTA   0,5ml 0,5M 
5mM 2ME)   add fresh before use 
 
+ 100g proteinase K per sample 
PCI (phenol chloroform isoamyl alcohol) extraction and EtOH precipitation 
 
 To the 400µl Proteinase K treated mix, add these separately: +50µl 3M NaAc pH 5.5 
+ 500µl PCI and centrifuge at max speed and 4oC for 30 minutes and carefully collect 
the upper phase. 
RNA will stay in the aqueous phase, the upper phase, and proteins will be in the 
lower/organic phase. 
 
 Added:   20g glycogen 
             1ml 100% EtOH 
Incubate for 30 mins at -80oC 
  
 Spin max speed in cold centrifuge, 30 mins 
 2 washes with 70% EtOH, air-dry 
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Phosphorylation & 5’ Linker Ligation 
 Pellet resuspended in          12.5ul water 
           1.5 ul 10 x RNA ligase I buffer (with 1mM ATP) 
           1ul PNK  
Incubate - 30’, 37C 
 
 1µl 5’ linker - remember to use a different primer for each sample i.e. for 
distinguishing them during deep sequencing results analysis.  
0.5µl 10 x RNA ligase I buffer  
 1µl RNA ligase I 
 2.5µl water 
 Total vol = 20µl    
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Day 4/5 (full day ~9hrs) 
 
PCI extraction and EtOH precipitation 
 Reaction mixture + 360µl water + 40µl 3M NaAc pH 5.5 + 500µl PCI  upper phase 
collected 
 Added:  1µl glycogen (20µg) 
450µl EtOH 
 
 Incubate at -20C, for a few hours. 
 
 Spin max speed in cold centrifuge, 30 mins. 
 2 washes with 70% EtOH, air-dry 
 
Reverse transcription:         
 Pellets resuspended in 13µl of the mix:  
4µl dNTPs [2.5mM]   
1µl of 3’ miRCat RT (10µM) (DNA primer which is reverse compliment to the 3’ 
linker) 
 8µl water  
  
 Incubate – 3 mins, 80oC 
 Incubate - 5’, on ice 
        
 Add 6µl of the mix:  4µl First strand buffer    
1µl 0.1M DTT     
1µl RNAsin     
 Incubate – 3 mins, 50oC 
 
 Add 1µul Superscript III, incubate - 1hr, 50oC 
 Inactivate Superscript – 15mins , 65oC 
 Degrade RNA – add 2µl RNAse H, incubate 30 mins, 37oC 
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PCR  
Set 4 PCR reactions for each sample with 2.5µl of input per reaction (10µl of cDNA from the 
previous step, half of the total)  
 
PCR mix  
Tot vol = 50µl for each reaction 
 
H2O    35µl 
buffer 10X   5µl 
dNTP 2.5mM each  5µl 
P5 primer 10uM  1µl 
PE miRCat primer 10uM 1µl 
Takara Taq   0.5µl 
_____________________________ 
Input 2.5µl cDNA. 
Master mix for each sample 190µl, add 10µl of cDNA input and distribute in 4 PCR tubes. 
 
Control PCR – miR16 amplification 
 
PCR 1 control       PCR 2 control  
 
Tot vol = 20µl       Tot vol = 20µl 
 
H2O    14µl   H2O    14 µl 
Buffer 10X   2µl   Buffer 10X   2 µl 
dNTP 2.5mM each  2µl   dNTP 2.5mM each  2 µl 
P5 primer 10uM  0.4µl    PE miRCat primer 10uM 0.4 µl 
miR-16 Rev 10uM  0.4µl    miR-16 F 10uM  0.4 µl 
Takara Taq   0.2µl   Takara Taq   0.2 µl 
______________________________  _____________________________ 
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After PCR pool the 4 reactions together and purify with Qiagen QIAquick columns. 
USE MINIELUTE COLUMNS! (stored at 4oC) 
Elute in 15µl of EB buffer add 3.5µl of loading 6x 
 
Prepare 3% Metaphor agarose gel: 
Weigh the agarose, add TBE 1x and leave on ice for 20 min (to avoid foaming). Microwave to 
dissolve, add syber safe (1:10000, Invitrogen 533102). Let it solidify then transfer to 4oC for 
20 mins before running.  
 
Run the gel with the tank on ice. 80 Volts for 1.5-2 hours 
 
Check gel at phosphoimager resolution 100µm. IMPORTANT: Print at 100% the image of the 
gel including margins and wells.  
 
Draw on printout the square you will cut and put in the order from bottom to top: printout, 
transparent film (the one for slides) and the gel on the top. Align the margins of the gel and 
the wells then cut the bands. At this point the bands from different samples can be pooled.  
 
Samples can be purified with Qiaquick gel extraction. 
NOTE: dissolve agarose at 37C and use MINIELUTE columns. 
 
Elute in 10µl H2O per column. This is the final product.  
NOTE: Read concentration with the fluorescence method, more accurate. 
 
Cloning for small scale sequencing 
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Leave 30mins at RT and then transform in Top10 one shot 
1µl of the ligation with one aliquot of Top10 
 
30 mins on ice, Heat shock competent cells 30 sec 42C and then 2 mins ice. 
 
Resuspend in pre-warmed SOC and incubate at 37oC for between 30 mins and 1h before 
plating on an ampicillin plate and incubating at 37oC. 
 
Colonies are individually picked and DNA purified for sequencing using the M13 primer. 
 
 
 
 
 
